Characterization of murine soluble CD137 and its biological activities by SHAO ZHE
 CHARACTERIZATION OF MURINE SOLUBLE CD137 










A THESIS SUBMITTED FOR THE DEGREE OF  
DOCTOR OF PHILOSOPHY IN SCIENCE 
DEPARTMENT OF PHYSIOLOGY 






I would first like to express my heartfelt gratitude to my supervisor, Associate 
Professor Herbert Schwarz, for his firm guidance and invaluable advices throughout 
the course of this project. I truly appreciate the encouragement and support that he 
gave me.  
 
Next, I would like to thank Poh Cheng and Teng Ee for teaching me the essential 
tissue culture techniques, Doddy and Sun Feng for helping me with the molecular and 
radioactive work, and Zulkarnain for supporting me with the tumor project. I would 
also like to thank our collaborator A/P Koh Daw Rhoon for providing mouse models 
for the testing of soluble CD137. 
 
Lastly, I offer my regards and blessings to all the members of A/P Herbert Schwarz’s 
lab who have supported me in any respect during the completion of the project. 
ii 
 
TABLE OF CONTENTS 
ABSTRACT ................................................................................................................... v 
LIST OF TABLES ....................................................................................................... vii 
LIST OF FIGURES .................................................................................................... viii 
LIST OF ABBREVIATIONS ........................................................................................ x 
CHAPTER 1 INTRODUCTION ................................................................................... 1 
1.1 Biology of the CD137 receptor/ligand system ........................................................... 2 
1.1.1 Expression of CD137 ......................................................................................... 2 
1.1.2 Expression of CD137 ligand .............................................................................. 3 
1.1.3 Costimulatory activities of CD137 .................................................................... 4 
1.1.4 CD137 as a coinhibitory molecule ..................................................................... 7 
1.1.5 Reverse signaling through CD137 ligand .......................................................... 9 
1.2 Involvement of CD137 receptor/ligand in cancer .................................................... 11 
1.2.1 Expression of CD137 receptor/ligand in cancer .............................................. 11 
1.2.2 Possible roles of CD137 as a neoantigen on cancer cells ................................ 12 
1.3 Soluble CD137 ......................................................................................................... 13 
1.3.1 Expression of soluble CD137 .......................................................................... 13 
1.3.2 Soluble CD137 as an antagonist to membrane-bound CD137 ......................... 14 
1.3.3 Soluble CD137 in diseases ............................................................................... 16 
1.4 Research objectives .................................................................................................. 18 
CHAPTER 2 MATERIALS AND METHODS .......................................................... 20 
2.1 Animals .................................................................................................................... 20 
2.2 Cells and cell culture ................................................................................................ 20 
2.3 Antibodies and reagents ........................................................................................... 21 
2.4 Isolation of murine splenocytes ............................................................................... 22 
2.5 Induction of murine soluble CD137 ......................................................................... 22 
2.6 Measurement of soluble CD137 by ELISA ............................................................. 22 
2.7 Measurement of membrane-bound CD137 by flow cytometry ............................... 23 
2.8 Measurement of stability of murine soluble CD137 ................................................ 23 
2.9 Reverse transcription polymerase chain reaction (RT-PCR) ................................... 23 
2.9.1 Isolation of total RNA from cells ..................................................................... 23 
2.9.2 Reverse transcription ....................................................................................... 24 
2.9.3 Polymerase chain reaction (PCR) .................................................................... 25 
iii 
 
2.10 Isolation of CD4+ and CD8+ cells from mouse spleen ............................................. 26 
2.11 Size exclusion chromatography (SEC) .................................................................... 26 
2.12 Western blot ............................................................................................................. 27 
2.13 Measurement of binding of soluble CD137 to CD137L recombinant protein ......... 27 
2.14 Measurement of binding of soluble CD137 to CD137L-expressing cells ............... 28 
2.15 Depletion of soluble CD137 .................................................................................... 28 
2.16 Isolation of regulatory T cells .................................................................................. 28 
2.17 Isolation of dendritic cells from mouse spleen ........................................................ 29 
2.18 Differentiation of dendritic cells from bone marrow ............................................... 29 
2.19 Generation of stable, CD137-expressing cell lines .................................................. 30 
2.19.1 Plasmids ........................................................................................................... 30 
2.19.2 Transfection ..................................................................................................... 31 
2.19.3 Measurement of membrane-bound CD137 expression on transfected cells .... 32 
2.19.4 Selection of stably-transfected clones .............................................................. 32 
2.20 Measurement of cell viability by manual cell counting ........................................... 33 
2.21 Measurement of cell proliferation via 3H-thymidine incorporation ......................... 33 
2.22 Lymphokine activated killer (LAK) cells assay for A20 cells ................................. 34 
2.23 Coating of proteins or antibodies in tissue culture plate .......................................... 35 
2.24 Treatment of A20 cell with agonistic anti-CD137 antibodies ................................. 35 
2.25 Measurement of cytokine secretion by ELISA ........................................................ 35 
2.26 Nuclear Factor κB (NF-κB) Assay........................................................................... 36 
2.27 Induction of subcutaneous tumor in syngeneic mouse models ................................ 36 
2.28 Statistics ................................................................................................................... 37 
CHAPTER 3 RESULTS .............................................................................................. 38 
3.1 Generation of murine soluble CD137 ...................................................................... 38 
3.1.1 Soluble CD137 is secreted by activated splenocytes ....................................... 39 
3.1.2 Soluble CD137 is released by T cells .............................................................. 45 
3.1.3 Expression of soluble CD137 by regulatory T cells ........................................ 48 
3.1.4 Expression of soluble CD137 by DC ............................................................... 52 
3.1.5 Summary .......................................................................................................... 58 
3.2 Potential agonistic function of murine soluble CD137 ............................................ 59 
3.2.1 Examination of the size of soluble CD137 ...................................................... 59 
3.2.2 Soluble CD137 can bind to CD137L ............................................................... 66 
3.3 Regulatory function of murine soluble CD137 ........................................................ 69 
3.3.1 Correlation of soluble CD137 with AICD ....................................................... 69 
iv 
 
3.3.2 Soluble CD137 regulates cytokine secretion ................................................... 72 
3.4 Correlation of soluble CD137 levels with diseases .................................................. 76 
3.5 Effects of soluble CD137 in tumorigenesis ............................................................. 78 
3.5.1 Screening of tumor cell lines for CD137 expression ....................................... 79 
3.5.2 Generation of stable, CD137-expressing B16 cell lines .................................. 82 
3.5.3 Generation of stable, CD137-expressing A20 cell lines .................................. 87 
3.5.4 Morphological changes of A20 cells upon agonistic antibody stimulation ..... 91 
3.5.5 CD137 signaling into A20 cells activates the NF-κB pathway ........................ 93 
3.5.6 Cytokine secretion of A20 cells upon stimulation of CD137 signaling ........... 96 
3.5.7 CD137 expression and protection against lymphokine activated killer (LAK) 
cells-mediated cytotoxicity ............................................................................................ 101 
3.5.8 in vivo tumor assays ....................................................................................... 104 
3.5.9 Summary ........................................................................................................ 109 
CHAPTER 4 DISCUSSION ...................................................................................... 110 
4.1 Summary of results ................................................................................................ 110 
4.2 Expression and generation of soluble CD137 ........................................................ 112 
4.3 Soluble CD137 antagonizes membrane-bound CD137 ......................................... 114 
4.3.1 Mechanisms of action of soluble CD137 ....................................................... 114 
4.3.2 Soluble CD137 as a general immunomodulator ............................................ 116 
4.4 Applications of soluble CD137 .............................................................................. 118 
4.5 CD137 as a neoantigen .......................................................................................... 120 
4.5.1 Signaling into CD137-expressing tumor cells ............................................... 121 
4.5.2 Effects of tumor-expressing CD137 on host immune cells ........................... 124 
4.6 Future work ............................................................................................................ 127 
4.7 Conclusion ............................................................................................................. 128 
REFERENCES .......................................................................................................... 130 
APPENDIX I MEDIA AND BUFFERS ................................................................... 138 





CD137 is a member of the tumor necrosis factor receptor family, and is involved in 
the regulation of a range of immune activities. Soluble forms of CD137 may 
antagonize membrane-bound CD137 and regulate host immune responses. Here we 
report in this study that soluble CD137 can be generated by differential splicing and is 
mainly released by activated T cells. While CD8+ T cells express significantly more 
membrane-bound CD137 than CD4+ T cells, both T cell subsets express similar levels 
of sCD137, resulting a two-fold increased ratio of soluble to membrane-bound CD137 
for CD4+ T cells. Other immune cells that express soluble CD137 include Treg and 
dendritic cells. Expression levels of soluble CD137 correlate with those of membrane-
bound CD137 in most cases except for DC. Soluble CD137 exists as a trimer and a 
higher order multimer and can bind to CD137 ligand, suggesting it has antagonistic 
effect on membrane-bound CD137. Levels of soluble CD137 correlate with activation 
induced cell death and depletion of soluble CD137 results in increase of IL-10 and IL-
12. Soluble CD137 is present in sera of mice with autoimmune disease but is 
undetectable in sera of healthy mice. 
 
Besides its expression in immune cells, CD137 was also found to be expressed in 
certain cancer cells. The correlation of CD137 expression and malignancy points to a 
selection advantages that CD137 expression provides to the tumor. The potential role 
of CD137 as a cancer neoantigen was characterized in this study. Using cell lines 
which overexpress CD137, it was found that CD137 signaling in B cell lymphoma 
A20 induces activation of the NF-κB pathway, which is accompanied by changes of 
cell morphology and IL-10 production. However, the effect of CD137 was not 
observed in vivo, as no significant difference could be found between the growth rates 
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of tumors formed by CD137-expressing and control A20 cells. Further studies will be 
needed to characterize the role of CD137 in tumorigenesis and possible antagonistic 
effect of soluble CD137 in this process. 
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CHAPTER 1 INTRODUCTION 
CD137 (4-1BB, ILA, TNFRSF9) is a member of the tumor necrosis factor receptor 
(TNFR) superfamily. Like the other members of the family, CD137 performs 
important regulatory functions at various stages of immune responses. The best-
known function of CD137 is that it provides costimulatory signals for T cells. 
Crosslinking of CD137 on activated T cells enhances proliferation, survival, cytolytic 
activity and immunological memory. The ligand of CD137 (CD137L, 4-1BBL, 
TNFSF9) belongs to the tumor necrosis factor (TNF) superfamily. CD137L is a 
transmembrane protein expressed by professional antigen presenting cells (APC). 
Together with CD137, which provides costimulatory signals to T cells, the CD137 
receptor/ligand pair can therefore form a potent proinflammatory system enhancing 
immune responses by stimulating APC as well as T cells. 
 
Besides its expression on immune cells, CD137 has also been found to be expressed 
in certain tumors but not corresponding healthy tissues. The correlation of CD137 
with tumors indicates that CD137 may contribute to the survival of tumor cells. 
However, further research needs to be done to reveal the underlying mechanisms. 
 
A soluble form of CD137 (soluble CD137) has been identified in man and has been 
shown to be generated by differential splicing of CD137 mRNA (Michel et al., 1998). 
Studies using recombinant CD137 proteins indicate that soluble CD137 can 
antagonize the costimulatory activities of the membrane-bound CD137 and reduce T 
cell proliferation. Interestingly, enhanced levels of soluble CD137 can be detected in 
sera of autoimmune, leukemia and lymphoma patients. Compared to its membrane-
bound counterpart, soluble CD137 has been much less studied. Considering the 
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possible role of soluble CD137 in antagonizing membrane-bound CD137 and in 
regulating immune responses, it is important to examine the expression and regulation 
of soluble CD137.  
 
In this chapter, the biology of the CD137 receptor/ligand system will be introduced 
first. This will be followed by a description of its involvement in cancer. Finally the 
biology and possible functions of soluble CD137 will be discussed. 
 
1.1 Biology of the CD137 receptor/ligand system 
1.1.1 Expression of CD137 
CD137 was first identified in the murine system in a screen for receptors on 
Concanavalin A (Con A) - activated T cells (Kwon and Weissman, 1989) and 
designated 4-1BB.  The human homologue was isolated independently from activated 
human T cells and termed originally induced by lymphocyte activation (ILA) 
(Schwarz et al., 1993).  
 
Expression of CD137 is strictly activation dependent in primary cells. CD137 is not 
detectable on resting T cells (Schwarz et al., 1995). However, when T cells are 
activated, expression of CD137 is strongly induced on both CD4+ and CD8+ T cells 
(Garni-Wagner et al., 1996; Kwon et al., 1987; Pollok et al., 1993). Other immune 
cells that express CD137 include monocytes, natural killer (NK) cells, dendritic cells 
(DC), follicular dendritic cells (FDC) and regulatory T cells (Treg) (Choi et al., 2004; 
Futagawa et al., 2002; Lindstedt et al., 2003; Melero et al., 1998; Pauly et al., 2002). 
Expression of CD137 is not restricted to immune cells. Chondrocytes, neurons, 
astrocytes, microglia and endothelial cells can also express CD137 on their surface 
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(Curto et al., 2004; Drenkard et al., 2007; Olofsson et al., 2008; Reali et al., 2003; von 
Kempis et al., 1997). In addition, expression of CD137 could be related to the 
progressing of diseases such as cancer as expression of CD137 has been reported in 
osteosarcoma (Lisignoli et al., 1998). 
 
CD137 is a type-I transmembrane protein which belongs to the TNF receptor 
superfamily. The gene of murine CD137 is located on mouse chromosome 4. CD137 
is made up of eight exons and seven introns. The nucleotide sequence of CD137 
contains a single reading frame that encodes a polypeptide of 256 amino acids (aa) 
with a calculated molecular weight of 27 kDa (Vinay and Kwon, 2006). The first 23 
aa constitute a signal peptide followed by a 63 aa extracellular domain. Amino acids 
186-211 constitute the hydrophobic transmembrane domain which lies in exon 7. The 
remaining 45 aa form the cytoplasmic domain which is necessary for signal 
transduction. Human CD137 is located on chromosome 1p36 (Schwarz et al., 1997). 
It contains 255 aa and has a predicted molecular weight of 27 kDa. There is 60% 
amino acid identity between human and murine CD137, including five conserved 
regions in the cytoplasmic domain, indication that they may be important for CD137 
functions. 
 
1.1.2 Expression of CD137 ligand 
The ligand of CD137, CD137L is a type-II transmembrane glycoprotein consisting of 
254 aa in man and 309 aa in mouse (Alderson et al., 1994; Goodwin et al., 1993). 
CD137L is expressed mainly on antigen presenting cells (APC), including B cells, DC 
and monocytes/macrophages. Human and murine transformed B cells express 
CD137L protein constitutively while activation may be required for primary B cells 
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(DeBenedette et al., 1997; Palma et al., 2004; Pollok et al., 1994; Zhou et al., 1995). 
CD137L is also expressed constitutively on peripheral monocytes and 
monocyte/macrophage cell lines (Futagawa et al., 2002; Ju et al., 2003; Laderach et 
al., 2003; Pollok et al., 1994). In DC, CD137L is expressed at low levels in both 
murine and human system. However, it can be enhanced by proinflammatory stimuli, 
including IL-1, CD40 ligand, LPS and double stranded RNA (Futagawa et al., 2002; 
Kim et al., 2002; Laderach et al., 2003; Lee et al., 2003). 
 
Besides APC, CD137L is also present on murine and human T cell lines while the 
expression of CD137L in murine and human primary T cells was either not detectable 
or only at low levels (Polte et al., 2007). A number of human carcinoma cell lines 
derived from the colon, lung, breast, ovary and prostate have also been reported to 
express CD137L (Salih et al., 2000).  
 
1.1.3 Costimulatory activities of CD137  
CD137 has been identified as a potent T cell costimulatory molecule. Upon signals 
from the T cell receptor (TCR), CD137 expression is upregulated on the T cell surface. 
Interaction of CD137 with its ligand or agonistic anti-CD137 antibodies induces 
proliferation and cytokine production of activated T cells (Alderson et al., 1994; 
DeBenedette et al., 1995; Goodwin et al., 1993; Pollok et al., 1993). Enhanced cell 
survival has also been observed as engagement of CD137 by CD137L leads to 
inhibition of activation-induced cell death (AICD), which correlates with the 





The costimulation of T cells through CD137 is CD28-independent but can synergize 
with CD28. CD137L-expressing APC were able to stimulate T cells purified from 
CD28-/- mice, suggesting that CD137 provides costimulatory signals to T cells in-
dependently from CD28 signaling (DeBenedette et al., 1997). Like murine CD137L, 
human CD137L can also stimulate CD28-deficient T cells, resulting in cell division, 
inflammatory cytokine production, enhancement of cytolytic effector function, as well 
as the upregulation of anti-apoptotic gene expression (Bukczynski et al., 2003). Other 
studies have shown that CD28 and CD137 synergize in the induction of IL-2 release 
by T cells, and a recombinant CTLA-Ig protein partially blocked CD137L-dependent 
IL-2 production (Wen et al., 2002). In addition, artificial APC coexpressing ligands 
for CD28 and CD137 synergistically enhanced T cell proliferation and survival, 
compared with CD28 alone (Maus et al., 2002). Taken together, these findings 
indicate that CD137L can promote CD28-independent T cell activation, but the 
combination of CD28 and CD137-mediated costimulation is more effective than 
either signal alone. 
 
Consistent with the in vitro findings, studies from murine models of tumors, viral 
infection, graft versus host disease (GVHD) and transplantation have clearly 
suggested a potent costimulatory role of CD137 on CD8+ T cells. In an in vivo 
adoptive transfer model, blocking of CD137 by a CD137-Fc fusion protein 
significantly reduced CD8+ T cell clonal expansion. This was due to a reduction in T 
cell division and enhanced apoptosis of CD8+ T cells (Cooper et al., 2002). 
Administration of anti-CD137 antibodies in vivo promoted rejection of cardiac and 
skin allografts in a GVHD model by amplifying the generation of H2d-specific 
cytotoxic T cells (Shuford et al., 1997). The same antibody was able to prevent tumor 
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progression and was even effective in eradicating established tumors by the induction 
of potent CD8+ T cell-mediated immune responses (Melero et al., 1997).  
 
Despite the variety of cell types that CD137 is expressed on, the studies of CD137 
signaling have been mainly focused on T cells. Upon aggregation, CD137 recruits 
tumor necrosis factor receptor-associated factor 1 (TRAF1) and TRAF2, leading to 
activation of nuclear factor κB (NF-κB) and the extracellular signal regulated kinase 
(ERK), c-Jun N-terminal kinase (JNK) and p38 mitogen-associated protein (MAP) 
kinase cascades (Figure 1). NF-κB signaling increases transcription of the anti-
apoptotic genes, bcl-XL and bfl-1, which in turn enhance T cell survival. In addition, 
CD137 can also promote T-cell survival through the TRAF1 and ERK-dependent 
downregulation of the proapoptotic molecule Bim (Wang et al., 2009). 
 
 
Figure 1. CD137 (4-1BB) signaling pathways in T cells. (Adopted from Wang et al., 
2009). Upon recruitment of TRAF1 and TRAF2, CD137 activates NF-κB, ERK, JNK 
and p38 MAPK signaling cascades. CD137 promotes T cell survival through 
upregulation of the anti-apoptotic genes bcl-XL and bfl-1 and the dwonregulation of 
the pro-apoptotic molecule Bim. 
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1.1.4 CD137 as a coinhibitory molecule 
In contrast to the costimulatory effects of CD137 in vitro and in vivo, several recent 
studies show that a CD137 agonist might also be inhibitory to some immune 
responses in vivo. As mentioned earlier, administration of anti-CD137 antibodies to 
tumor-bearing or allografted mice induced a potent CD8+ T cell response. However, 
when the same antibody was injected into previously immunized mice, it suppressed 
development of T-dependent humoral immunity. In other words, mice injected with 
anti-CD137 antibody were unable to generate a CD4+ T cell-dependent humoral 
immune response to the T-dependent antigens used for immunization (Mittler et al., 
1999).  
 
The inhibitory effect of the anti-CD137 antibody was also observed in mice with 
autoimmune diseases. In NZB/NZW lupus-prone mice, anti-CD137 treatment has 
been shown to be effective in controlling the development of systemic lupus 
erythematosus (SLE). Administration of anti-CD137 antibodies inhibited production 
of anti-DNA antibodies. Mice in the treatment group no longer maintained pathogenic 
IgG autoantibody production and achieved an extension of lifespan from 10 months to 
more than 2 years (Foell et al., 2003). Anti-CD137 antibodies can also affect the 
development of collagen-induced arthritis (CIA). Injection of anti-CD137 antibody 
into DBA/1J mice immunized with bovine collagen II has been shown to prevent 
disease development and to inhibit humoral immune response against collagen II. 
Furthermore, it induced a protective memory in the mice, enabling resistance to 
subsequent challenges with the same antigen (Foell et al., 2004). Similar results were 
obtained by other groups in the CIA model and in a model for experimental 
autoimmune uveoretinitis (EAU), where administration of anti-CD137 antibody 
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inhibited disease development and reduced even established disease (Seo et al., 2004; 
Choi et al., 2006). In both models a massive expansion of CD11c+CD8+ cells and 
accumulation of indoleamine 2,3-dioxygenase (IDO), which is a downstream effector 
of IFN-γ were found. Addition of either anti-IFN-γ or 1-methyltryptophan, an 
inhibitor of IDO, reversed the inhibitory effect of anti-CD137 on disease activity (Seo 
et al., 2004; Choi et al., 2006). 
 
The effect of CD137 signaling on another subset of T cells, the CD4+CD25+ Treg, has 
not been resolved as contradictory data have been obtained by different groups. 
CD137 was expressed constitutively on freshly isolated CD4+CD25+ cells at low 
levels and its expression could be upregulated upon activation. Addition of an anti-
CD137 antibody in vitro abrogated CD4+CD25+ cell-induced suppression on 
CD4+CD25- cells. The same antibody was also effective in reversing a Treg-induced 
delay of GVHD in vivo, resulting in accelerated disease progression and death. The 
same results could be obtained when using CD4+CD25- cells from CD137-deficient 
mice, indicating a direct role of CD137 in the regulation of Treg cell functions (Choi 
et al., 2004). Consistent with these findings, Morris et al. found that CD137 signaling 
inhibits CD4+CD25+ Treg-mediated tolerance in a murine experimental autoimmune 
thyroiditis model (Morris et al., 2003). In sharp contrast to the above findings 
showing an inhibitory effect of CD137 on CD4+CD25+ T cells, Zheng et al. recently 
reported that the CD137 signal was strongly costimulatory for CD4+CD25+ T cells, 
both in vitro and in vivo. Furthermore, the CD137-expanded CD4+CD25+ T cells were 
functional, as they remained suppressive to other T cells in coculture experiments 




1.1.5 Reverse signaling through CD137 ligand 
The ligands of the TNF receptor family members, the members of the TNF family, are 
also expressed as membrane-bound molecules and many of them, such as FasL and 
CD40L, can also transduce signals into the cells they are expressed on(Eissner et al., 
2004). In such cases the receptor/ligand systems mediate bidirectional signaling and 
both molecules function simultaneously as ligands and as receptors (Eissner et al., 
2004). Reverse signaling refers to signal transduction of the so-called ligands which 
carry the name ‘ligand’ for historical rather than functional reasons. Bidirectional 
signaling is rare but not unique to the TNF receptor/ligand family members as it also 
occurs in the ephrin/Eph receptor family and also for B7-CD28 (Wilkinson, 2000; 
Orabona et al., 2004). 
 
Signal transduction through CD137L is one of the best studied cases of reverse signal 
transduction (Schwarz, 2005). Best known are the effects of reverse CD137L 
signaling in APC (Figure 2). In monocytes CD137L signaling triggered by 
recombinant CD137 protein or anti-CD137L antibody induces activation and 
migration, prolongs survival and leads to cell growth (Drenkard et al., 2007; Ju et al., 
2003; Langstein et al., 2000; Langstein et al., 1998; Langstein and Schwarz, 1999; 
Langstein et al., 1999). CD137L associates with CD14 and possibly other Toll-like 
receptors, and synergistically regulates TNF release (Kang et al., 2007).  
 
In DC, reverse signaling enhances maturation of immature DC, leading to higher 
expression of CD80, CD86, major histocompatibility complex (MHC) class II and IL-
12, migration of DC and enhanced capacity to stimulate T cell responses (Laderach et 
al., 2003; Kim et al., 2002; Lippert et al., 2008). 
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Little is known of the effects of reverse CD137 signaling in B cells except for 
costimulation of proliferation and immunoglobulin secretion (Pauly et al., 2002). 
Interestingly, CD137 is expressed on FDC in germinal centers where B cells migrate 
after first antigen contact and where they undergo affinity maturation. FDC-expressed 
CD137 may participate in costimulation of B cells that bind more tightly to FDC-
displayed antigen, once they have rearranged their B cell receptors to higher affinity 
ones (Lindstedt et al., 2003; Pauly et al., 2002).   
 
Reverse signaling may also take place in T cells, and contrary to the situation in APC, 
the CD137L signal has been shown to inhibit proliferation and to induce apoptosis in 
human T cells (Schwarz et al., 1996; Ju et al., 2003; Michel et al., 1999). However, 
recent work in our lab suggested that the inhibitory effect of CD137 on T cells might 
be an indirect one, which could be induced by CD137-primed monocytes (personal 
communication, Shaqireen D/O Kwajah). In sharp contrast to the above findings, a 
recent study found that CD137L signaling in murine T cells induces IFN-γ release, 
contributing to immune deviation and an inhibition of Th2-mediated allergic lung 
inflammation (Polte et al., 2007). 
 
In monocytes, part of the signaling pathway initiated by CD137L has been elucidated. 
Protein tyrosine kinases, p38 MAPK, ERK, MAPK/ERK kinase, phosphoinositide-3-
kinase and protein kinase A are involved, demonstrating that the exotic concept of 




Figure 2. Bidirectional signal transduction and reverse signaling in the CD137 
receptor/ligand system. Crosslinking of CD137 and CD137L leads to activation of 
APC and costimulation of T cells simultaneously. 
 
 
1.2 Involvement of CD137 receptor/ligand in cancer 
1.2.1 Expression of CD137 receptor/ligand in cancer 
CD137 expression has been reported in several cancers. Human carcinoma cell lines 
derived from osteosarcoma (Lisignoli et al., 1998) and lung cancer (Zhang et al., 
2007b) have been shown to express CD137 constitutively. In the case of lung cancer, 
CD137 has also been detected in tumor tissue samples, but not in corresponding 
controls from healthy tissues (Zhang et al., 2007b).  In a recent study conducted in 
NUS, a number of tissue microarrays were screened for the expression of CD137 via 
immunohistochemistry. CD137 was found to be expressed by tumor cells in B-cell 
lymphoma and rhabdomyosarcoma.  (unpublished data, B. Z. Quek). 
 
In a number of solid tumors, CD137 was not detected on the cancerous cells, but 
rather, on the cells of the blood vessel walls in these tumors. A study involving 
immunohistochemical staining of frozen tissue sections found that 32% of malignant 
and 14% of benign tumor tissues contained blood vessels that stained positive for 
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CD137 (Broll et al., 2001). In contrast, none of the paired normal tissues contained 
blood vessels that expressed CD137. Tumor tissues containing CD137-positive blood 
vessels included fibrosarcoma, nephroblastoma and ameloblastoma.  
 
Unlike CD137, the presence of CD137L has only been reported in cell lines that 
originated from colon, lung, breast, ovarian or prostate cancer (Salih et al., 2000), but 
not in actual tumor tissues. Therefore, in the absence of such evidence, the association 
between CD137L and cancer remains to be substantiated. 
 
1.2.2 Possible roles of CD137 as a neoantigen on cancer cells 
The association of CD137 with tumor tissues suggests that tumor cells may gain 
survival advantages by expressing CD137. Several hypotheses might be able to 
explain this correlation.  
 
Firstly, CD137 might exert its effects on immune effector cells, namely cytotoxic T 
lymphocytes (CTL) and NK cells, which are responsible for anti-tumor immune 
responses. One possible mechanism involves reverse signaling through CD137L in T 
cells, which results in T cell death. Hence, cancer cells may express CD137 in order 
to engage CD137L on T cells, so as to induce T cell apoptosis and consequently, 
escape immune surveillance. This scenario would be analogous to the expression of 
Fas ligand (FasL) by cancer cells. In the “Fas counter-attack hypothesis”, FasL 
expressed on cancer cells is hypothesized to interact with Fas expressed on activated 




Another possible reason may be that the presence of CD137 on tumor blood vessels 
leads to an increased ability to recruit monocytes to the tumor site (Drenkard et al., 
2007). Monocytes can subsequently differentiate into macrophages, and as tumor 
associated macrophages can promote tumor angiogenesis and support tumor growth 
and metastasis (Mantovani et al., 2004). 
 
As mentioned earlier, CD137 signaling upregulates the expression of the anti-
apoptotic proteins Bcl-XL and Bfl-1, therefore the engagement of CD137 on cancer 
cells can potentially enhance survival and proliferation. This likely occurs when 
CD137L-expressing APC come into contact with the cancer cells. Anti-apoptotic 
proteins in the Bcl-2 family have oncogenic potential and may be involved in the 
inhibition of maliganant cell apoptosis (Cory et al., 2003). Because of this, it is 
possible that CD137 expression is able to provide survival advantages for cancer cells. 
 
1.3 Soluble CD137 
1.3.1 Expression of soluble CD137 
Soluble isoforms are a common occurence of the members of the TNFR family. These 
soluble isoforms are generated either by alternative splicing of the mRNA or by 
cleavage of membrane-bound receptors by matrix metalloproteinase. Soluble forms of 
CD95, CD40 and CD137 are generated by differential splicing while the rest of the 
family are by proteolytic cleavage (Lotz et al., 1996).  
 
Soluble CD137 is a naturally occurring and endogenous inhibitor of CD137 activities. 
Soluble CD137 was first identified in 1995 when Serateh et al. (1995) found two 
isoforms of CD137 mRNA from mouse splenocytes and thymocytes. Both isoforms 
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were expressed in an activation-dependent manner and the smaller isoform was a 
mRNA splice variant lacking the exon encoding the transmembrane domain (Setareh 
et al., 1995). Human soluble CD137 protein was also identified and shown to be 
released by activated lymphocytes. Like murine soluble CD137, human soluble 
CD137 is generated by differential splicing and three mRNA variants have been 
identified (Michel et al., 1998). Expression of soluble CD137 does not strictly 
correlate with expression of membrane-bound CD137. A study using human 
peripheral blood mononuclear cells showed that levels of soluble CD137 correlate 
with AICD, indicating that soluble CD137 may provide a negative control mechanism 
for immune responses (Michel and Schwarz, 2000).  
 
1.3.2 Soluble CD137 as an antagonist to membrane-bound CD137 
The fact that expression of soluble CD137 does not correlate with proliferation, but 
with AICD, indicates that soluble CD137 may be utilized by the immune system to 
down-regulate immune responses mediated by membrane-bound CD137. Indeed, in 
vitro studies have shown that recombinant soluble CD137 protein antagonizes the 
activity of membrane-bound CD137 and abolishes CD137-mediated immunological 
activities. For example, DeBenedette found in 1995 that a fusion protein of CD137 
and alkaline phosphatase (CD137-AP) could block T cell activation. In particular, it 
could inhibit T cell proliferation and IL-2 production in both anti-CD3 stimulated 
splenocytes and a primary mixed lymphocyte reaction (MLR) (DeBenedette et al., 
1995). In the same year, Hurtado’s group used a soluble chimera of murine CD137 
with human Ig G (CD137-Fc) to study a potential role for the interaction of CD137 
receptor/ligand in T cell activation and compared its effect to that of the chimeric 
molecule CTLA-4-Ig, a reagent known to interfere with the interaction of CD28 with 
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B7 costimulatory receptors. They found that CD137-Fc could partially block the 
activation of T cells in both anti-CD3 stimulated splenocytes and MLR. Moreover, 
they also found that the blocking capacity of CD137-Fc and CTLA-4-Ig appears to 
correlate with the relative expression of their respective cognate receptors (CD137L 
and B7) on the accessory cell (Hurtado et al., 1995). Although results from these 
studies provide evidence for the possible antagonistic role of soluble CD137 on 
membrane-bound CD137, these results were not obtained under optimal conditions. 
Instead of studying physiological soluble CD137, both groups used recombinant 
CD137 protein conjugated with either AP or human IgG. It is unknown whether the 
inhibitory effect observed was actually derived from CD137 or other parts of the 
recombinant proteins. Moreover, neither of the two groups examined the underlying 
mechanisms of the inhibitory effect of soluble CD137.  
 
Therefore, one of the aims of this thesis is to confirm the antagonistic effect of soluble 
CD137 by using naturally produced soluble CD137 in the murine system, and more 
importantly to study the mechanism(s) that underlie the antagonistic effect. There are 
currently two possible explanations for the mechanisms. The first explanation, which 
is also a more common one, is that soluble CD137 competitively binds to CD137L 
and blocks its binding site for membrane-bound CD137 (Figure 3B). The other 
explanation is that soluble CD137 inserts into existing membrane-bound CD137 
trimers (Figure 3C). Examples for this explanation can be found in other members of 
the TNF family such as TNF (Deng et al., 2005). Because of the lack of an 





Figure 3. Schematic depiction of possible mechanisms of soluble CD137 action. In 
the absence of soluble CD137, signals can go through membrane-bound CD137 
(mCD137) upon crosslinking of CD137L (A). To antagonize mCD137-induced 
signaling, soluble CD137 (sCD137) may (B) compete with mCD137 for binding to 
CD137L or (C) insert into mCD137 trimers. 
 
 
1.3.3 Soluble CD137 in diseases 
Soluble CD137 has been reported to be expressed at elevated levels in sera of patients 
with multiple autoimmune diseases. In 1998, substantially increased levels of soluble 
CD137 were first observed in sera of patients with rheumatoid arthritis (RA) (Michel 
et al., 1998). Later studies (Jung et al., 2004) showed that serum levels of both soluble 
CD137 and soluble CD137L were significantly higher in RA patients compared with 
healthy controls. Moreover, levels of soluble CD137 and soluble CD137L correlated 
strongly with rheumatoid factor (RF) and disease severity. Sharief (2002) investigated 
soluble CD137 in patients with multiple sclerosis (MS), which is an inflammatory 
17 
 
demyelinating disease of the central nervous system (CNS) causing a variable degree 
of axonal damage. Significantly higher levels of soluble CD137 were found in serum 
and the intrathecal compartment of patients with clinically active MS when compared 
with patients with clinically stable MS or healthy individuals (Sharief, 2002). In 
addition, increased levels of soluble CD137 and soluble CD137L were also reported 
to be present in other autoimmune diseases such as SLE and Behcet’s disease (BD) 
(Jung et al., 2004). Recently, Furtner also found elevated levels of soluble CD137 in 
sera of patient in various haematological malignancies, especially in chronic 
lymphocytic leukemia (CLL) (Furtner et al., 2005). 
 
Accumulating data has shown the correlation of soluble CD137 with diseases. 
However, none of the studies has ever investigated the underlying mechanisms. This 
is partially due to the lack of appropriate experimental mouse models. There is no 
report on the correlation of soluble CD137 with diseases in mice so far. Therefore, it 
is necessary to screen mouse disease models for the presence of soluble CD137. By 
doing this, appropriate models can be selected for further studies to explain the 
presence of soluble CD137 in the respective diseases and its possible implications. 
Because of the bidirectional signaling of CD137 receptor/ligand interaction, the 
inhibitory effect of soluble CD137 on its membrane-bound counterpart could block 
the signal into both T lymphocytes and APC simultaneously. In that case, soluble 





1.4 Research objectives 
The objective of this study was to characterize the expression and functions of murine 
soluble CD137. More specifically, the following points will be examined in this thesis: 
i. Expression and regulation of membrane-bound and soluble forms of CD137. 
The presence of membrane-bound and soluble CD137 in different immune 
cell populations will be tested at the protein level by flow cytometry and 
ELISA, respectively. The protein expression will then be confirmed at the 
mRNA level by RT-PCR. Levels of soluble CD137 will be compared with 
membrane-bound CD137 in each cell type.  
ii. Antagonistic mechanism(s) of soluble CD137. The multimeric status of 
soluble CD137 will be examined by testing its size by Western blot and 
size exclusion chromatography (SEC). Naturally occurring soluble CD137 
will be used to test the binding ability of soluble CD137 to CD137L.  
iii. Regulatory functions of soluble CD137. Levels of soluble CD137 will be 
compared with the activation status of the cells by testing proliferation and 
cell death. The potential regulatory function of soluble CD137 will be 
examined by testing the cytokine profile in a cell culture system after 
depletion of soluble CD137.  
iv. Correlation of soluble CD137 and disease activity in mouse models. Sera from 
murine disease models and healthy controls will be measured for soluble 
CD137 levels by ELISA.  
v. Enhancement of tumor therapy by CD137 antagonists. Several murine tumor 
cell lines will be selected to establish tumor models. In detail, these cell 
lines will be transfected with CD137 expression vector. Stable CD137-
expressing tumor cell lines will be selected for in vitro and in vivo studies 
19 
 
to analyse a potential protective effect of membrane-bound CD137 on 
tumor cells. The antagonistic effects of soluble CD137 will then be 
determined by applying soluble CD137 in these assays.  
 
This thesis presents the first systematic study on murine soluble CD137. Results of 
the present study should contribute to the understanding of the expression and 
regulation of soluble CD137 in the murine system. The studies on the antagonistic 
mechanisms may also shed some light on how CD137 regulates various immune 
responses by switching its expression between different isoforms. The correlation of 
soluble CD137 in murine disease models may provide useful tools for follow-up 






CHAPTER 2 MATERIALS AND METHODS 
2.1 Animals 
Female Balb/C and C57/Bl6 mice between 16 and 20 weeks of age were used for 
extracting immune cells as well as inducing syngeneic tumor models. Balb/C MRL-
Faslpr/J (Balb/C lpr), C57/Bl6 MRL-Faslpr/J (C57/Bl6 lpr) and C57/Bl6Smn C3-
Faslgld/J (C57/Bl6 gld) were obtained from the Animal Holding Unit of the National 
University of Singapore (NUS). Animals were specific pathogen free, and kept with 
access to fresh food and water in the animal care facility at NUS under the 
institutional guidelines for usage of experimental animals. 
 
2.2 Cells and cell culture 
The B cell lymphoma cell line A20 was obtained from ATCC and was routinely 
cultured in RPMI 1640 (Sigma) supplemented with 10% fetal bovine serum (FBS), 
1 mM sodium pyruvate and 50 μM 2-mercaptoethanol (RPMI-S2-10, refer to 
Appendix I). B16.F0 is a melanoma cell line purchased from ATCC. B16.F0 cells 
were cultured in DMEM (Sigma) supplemented with 10% heat-deactivated FBS 
(DMEM-10, refer to Appendix I). Cells were passaged every 2-3 days, with B16.F0 
cells being detached using either Trypsin-EDTA (Gibco Invitrogen, Carlsbad, CA) or 
10 mM EDTA in phosphate buffered saline (PBS). All cells were kept in a humidified 
incubator at 37 °C with 5% CO2. All cell lines were Mycoplasma free and routinely 
checked by PCR-based tests (refer to Appendix II). 
 
Splenocytes were isolated from Balb/C or C57/Bl6 mice. CD4+ and CD8+ T cells 
were isolated by anti-CD4 or anti-CD8 antibody coupled to magnetic beads (Miltenyi, 
Bergisch Gladbach, Germany), respectively. Cells were cultured in RPMI-S2-10 
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supplemented with 0.1 mg/ml penicillin-streptomycin (Invitrogen) (RPMI-S2-10-P/S, 
refer to Appendix I). 
 
2.3 Antibodies and reagents 
Recombinant human CD137-Fc protein was purified from supernatants of stably 
transfected Chinese hamster ovary (CHO) cells by protein G sepharose, as described 
previously (Schwarz et al., 1996). Recombinant murine CD137-Fc protein was 
purchased from R&D Systems (Minneapolis, MN, USA). Recombinant murine 
CD137L-Flag protein and Flag protein were obtained from Alexis (Lausen, 
Switzerland). Human IgG1 Fc protein was purchased from Accurate Chemical and 
Scientific Corporation (Westbury, NY, USA). 
 
Biotin-conjugated, PE-conjugated and unconjugated anti-mouse CD137 monoclonal 
antibody (clone 17B5) and anti-mouse CD137L antibody (clone TKS-1) were 
obtained from eBioscience (San Diego, CA, USA). Anti-CD137 agonistic antibody 
(clone 3H3) is a gift from Dr Mark Smyth (University of Melbourne, Australia). Anti-
CD137 capture antibody (clone 158332), anti-CD137 agonistic antibody (clone 
158321), anti-CD137L antibody (clone 203942), biotinylated goat anti-mouse CD137 
polyclonal antibody and biotinylated goat anti-mouse CD137L polyclonal antibody 
were purchased from R&D Systems. Anti-CD3 (clone 17A2) and anti-CD28 (clone 
37.51) antibodies were purchased from Biolegend (San Diego, CA, USA). 
 
Con A, PHA, PMA and calcium-ionophore A23187 (A23187) were obtained from 




2.4 Isolation of murine splenocytes 
Mice were euthanized by CO2 inhalation. Spleens were gently dissected from the left 
flank of the mice and kept in sterile medium. Under sterile conditions, spleens were 
loaded onto a 70 µm cell strainer (BD) that is placed on top of a 50 ml falcon tube. To 
obtain single cell suspension, the spleens were pressed onto mesh using a syringe 
plunger. MACS buffer (refer to Appendix I) was added intermittently to release cells 
into the falcon tube. The collected cells were washed with MACS buffer and 
centrifuged at 400 g for 7 min. 1 ml of RBC lysis buffer (refer to Appendix I) was 
added to resuspend the cell pellet followed by incubation for no more than 1 min. The 
cells were then washed with MACS buffer and resuspended in RPMI-S2-10-P/S 
medium at the concentration of 3 × 106 cells/ml unless otherwise stated. 
 
2.5 Induction of murine soluble CD137  
Splenocytes from Balb/C and C57/Bl6 mice were activated by various stimuli 
including Con A, PHA, PMA with A23187, IL-2 and anti-CD3 and anti-CD28 
antibodies. Supernatants of the culture were collected at 24, 48 and 72 h. The 
presence of soluble CD137 in these cultures was then determined by enzyme-linked 
immunosorbent assay (ELISA). 
 
2.6 Measurement of soluble CD137 by ELISA 
The murine CD137 ELISA Duoset was purchased from R&D Systems. The ELISA 
was performed on cell culture supernatant or serum samples according to the 




2.7 Measurement of membrane-bound CD137 by flow cytometry 
Splenocytes activated by Con A were harvested at different time points. 2 × 105 cells 
were washed twice with PBS and stained with 50 μl of PE-conjugated anti-mouse 
CD137 or with Hamster IgG isotype control antibodies for 30 min at 4 ºC in dark. The 
antibodies were diluted in FACS buffer (PBS containing 0.5% FBS and 0.02% 
sodium azide) (refer to Appendix I). After staining, cells were washed twice with 
FACS buffer and resuspended in 500 µl of buffer for analysis using Cyan™ flow 
cytometer (DakoCytomation, Denmark). Results were analysed with Summit 4.3 
software (DakoCytomation, Denmark). 
 
2.8 Measurement of stability of murine soluble CD137 
Soluble CD137-containing supernatant was stored at 37 ºC for 7 days. An aliquot of 
supernatant was harvested daily and frozen at -20 ºC. All the samples collected were 
thawed at the end of the experiment and levels of soluble CD137 were measured by 
ELISA. 
 
2.9 Reverse transcription polymerase chain reaction (RT-PCR) 
2.9.1 Isolation of total RNA from cells 
Total RNA of splenocytes were extracted from Balb/C mice by using RNeasy Mini 
Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Briefly, 
2 × 106 cells were harvested and resuspended in 350 µl of buffer RLT. Cells were 
homogenized by passing through a 27 G needle for 5 times. 350 µl of 70% ethanol 
was added to homogenized lysate and well mixed. The whole solution was passed 
through the RNeasy mini-column by centrifugation at 13,200 rpm for 1 min to allow 
RNA binding to membrane. The flow through was discarded and buffers RW1, RPE 
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was applied successively to wash the column by centrifugation at 13,200 for 1 min. 
RNeasy column was then carefully transferred to a new 1.5 ml collection tube after 
the column was dried by centrifugation for 1 min at 13,200 rpm. To elute, 30 µl of 
RNase-free water was added directly onto the RNeasy silica-gel membrane and 
allowed to flow through the membrane by centrifugation at 13,200 rpm for 1 min. The 
concentration of RNA obtained from this procedure was evaluated by ND-1000 
UV/Vis spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). 
 
2.9.2 Reverse transcription 
The Fermentas RevertAid™ first strand cDNA synthesis kit (Hanover, MD, USA) 
was used for reverse transcription. 2 μg of total RNA and 1 μl of 0.5 μg/μl oligo 
(dT)18 primer were mixed in diethylpyrocarbonate (DEPC) treated water to a total 
volume of 12 μl. After a 5-minute incubation at 65 ºC to remove RNA secondary 
structure, reaction was quickly chilled on ice. The mixture was prepared according to 
Table 1 and reverse transcription was carried out at 42 ºC for 1 h and terminated at 70 
ºC for 5 min. First-strand cDNA obtained from this procedure was kept at -20 ºC.  
 
Table 1. Reverse transcription reaction mix. 
Components Stock concentration 
Final 
concentration Volume (μl) 
RNA/Oligo (dT)18 - - 12 
Reaction buffer 5 × 1 × 4 
RiboLockTM RNase inhibitor 20 U/μl 1 U/μl 1 
dNTPs  10 mM 1 mM 2 
RevertAidTM M-MuLV 
Reverse Transcriptase 
200 U/μl 10 U/μl 1 
Total volume - - 20 
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2.9.3 Polymerase chain reaction (PCR) 
Standard PCR reaction mix and thermal cycling program are listed in Table 2 and 
Table 3 respectively. Primers used for RT-PCR are summarized in Table 4. 
 
Table 2. Standard PCR reaction mix.  
Components  Stock concentration 
Final 
concentration Volume/Reaction 
cDNA template - - 50 ng or 2 µl 
Forward primer 25 µM 0.5 µM 0.5 µl 
Reverse primer 25 µM 0.5 µM 0.5 µl 
Taq DNA polymerase 5 U/µl 0.05 U/µl 0.25 µl 
Taq buffer 10 × 1 × 2.5 µl 
dNTPs 10 mM 200 µM 0.5 µl 
H2O - - Top up to 25 µl 
 
 
Table 3. RT-PCR thermal cycling program for examination of CD137 mRNA 
expression 
Step Process  Temperature (ºC) Time 
1 Initial melting 95 5 min 
2 Melting  95 30 sec 
3 Primer annealing * 45 sec 
4 Extension  72 1 min 
5 Repeat step 2-4 for 30 cycles - - 
6 Final extension 72 10 min 
* The primer annealing temperature is determined according to each primer pair. 
muCD137_F/muCD137_R, 50 ºC; GAPDH_F/GAPDH_R, 60 ºC; 





Table 4. Primers for RT-PCR for examination of CD137 expression. 
Primer Sequence Tm (ºC) 
muCD137_F 5' - atg gga aac aac tgt tac aac - 3' 55 
muCD137_R 5' - tca cag ctc ata gcc tcc tcc - 3' 63 
GAPDH_F 5'- tgg tat cgt gga agg act cat gac- 3’ 65 
GAPDH_R 5'- atg cca gtg agc ttc ccg ttc agc- 3’ 69 
 
 
2.10 Isolation of CD4+ and CD8+ cells from mouse spleen 
Helper and cytotoxic T cells were positively selected by magnetic activated cell 
sorting (MACS) using CD4 or CD8 microbeads (Miltenyi Biotec, Bergisch Gladbach, 
Germany), respectively. Briefly, freshly isolated splenocytes were labeled with CD4 
or CD8 microbeads for 15 min at 4 ºC. The labeled cells were then loaded into the 
MACS column which is placed in a strong magnetic field. After the negative fraction 
was eluted using MACS buffer, the column was removed from the magnetic field and 
the positively labeled cells were flushed out of the column. 
 
2.11 Size exclusion chromatography (SEC) 
Soluble CD137-containing supernatant was concentrated 40 times by Amicon ultra 
centrifugal filter unit 10 kDa (Millipore, Billerica, MA, USA). Samples were then 
subjected to a Superdex 200 10/30 size exclusion column using the Akta-Purifier 10 
system (Amersham-Pharmacia Biotech). 0.05 M phosphate buffer with 1 mM EDTA 
and 0.15 M sodium chloride, pH 7.4 was used as the mobile phase at a flow rate of 
0.5 ml/min. The injection volume for the sample or standards was 200 μl. The column 
was calibrated by protein HPLC markers Glutamate Dehydrogenase (290 kDa), 
Lactate Dehydrogenase (142 kDa), enolase (67 kDa), myokinase (32 kDa) and 
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cytochrome C (12.4 kDa) (USB bio, USA) which was detected by absorbance at 
280 nm. The presence of sCD137 in the fractions was detected by ELISA. 
 
2.12 Western blot 
A20/muCD137 or A20/pcDNA cells were lysed in modified RIPA buffer (50 mM 
Tris–HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 10 mM NaF, 1 mM Na3VO4, 1% 
NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and 1 × protease inhibitor cocktail 
from Roche) for 2 h at 4 ºC with gentle shaking. Cell lysates were separated on a 12% 
SDS-polyacrylamide gel and transferred to a PVDF membrane (Millipore, Billerica, 
MA, USA). The membrane was blocked and hybridized with a biotinylated goat anti-
mouse CD137 polyclonal antibody (R&D Systems) followed by Streptavidin-HRP 
(Sigma). Immunoactive bands were visualized using the Supersignal Western Pico 
chemiluminescent substrate (Pierce). 
 
2.13 Measurement of binding of soluble CD137 to CD137L recombinant protein 
CD137L-flag recombinant protein was pre-coated in 96 well tissue culture plates. 
Soluble CD137-containing supernatant was then added into the wells for 2 h at room 
temperature and captured soluble CD137 was detected by a biotinylated goat anti-
mouse CD137 polyclonal antibody, followed by incubation with streptavidin-
horseradish peroxidase (Strept-HPR) for 20 min at room temperature. Three washes 
with PBS, 0.05% Tween 20 (Bio-rad) (PBST) were performed after each step. 
Tetramethylbenzidine (TMB) substrate (Sigma) was used to visualize positive 




2.14 Measurement of binding of soluble CD137 to CD137L-expressing cells 
Soluble CD137-containing supernatant was concentrated 40 times by Amicon ultra 
centrifugal filter unit 10 kDa. The supernatant was then serial diluted in fresh medium 
and added to 24-well tissue culture plate containing 5 × 105 CD137L-expressing A20 
cells per well. The depletion of soluble CD137 in the supernatant was detected 24 h 
later.  
 
2.15 Depletion of soluble CD137 
Splenocytes were activated with 2 μg/ml Con A. The culture medium was removed 
from cells after 24 and 48 h and incubated for 2 h on plates to which either anti-
CD137 antibody or an isotype control had been immobilized before it was returned to 
the cells. The effect of depletion was detected by ELISA for soluble CD137. 
 
2.16 Isolation of regulatory T cells 
Regulatory T cells were isolated from mouse spleen using CD4+CD25+ Regulatory T 
Cell Isolation Kit (Miltenyi Biotec) following the manufacturer’s instructions. Briefly, 
freshly isolated splenocytes were labeled with a cocktail of biotinylated antibodies 
against an array of antigens (CD8a, CD11b, CD45R, CD49b and Ter-119 antibodies) 
that are not expressed on CD4+ T cells, followed by anti-biotin microbeads. The cells 
were also labeled with PE-conjugated CD25 antibody for further isolation at a later 
stage. The labeled cell suspension was then passed through a depletion column (LD 
column) in a strong magnetic field. Biotin-labeled cells tagged by the microbeads 
were retained in the column and only CD4+ T cells were collected in the effluent. 
Among these CD4+ cells, those expressing CD25 were labeled using anti-PE 
microbeads and then positively selected using two MS columns in a strong magnetic 
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field. The purity of isolated regulatory T cells was determined by flow cytometry 
using FITC-labeled anti-CD4, PE-labeled anti-CD25 and APC-labeled anti-FoxP3 
antibodies from Treg Detection Kit (Miltenyi Biotec). The cells were activated by 10 
µg/ml immobilized anti-CD3 antibody and 1000 U/ml IL-2 in vitro for the detection 
of membrane-bound and soluble CD137. 
 
2.17 Isolation of dendritic cells from mouse spleen  
Mouse DC was isolated from spleen using CD11c microbeads (Miltenyi). For highest 
recovery and purity of CD11c+ DC from mouse spleen, single-cell suspensions were 
prepared by enzymatic disaggregation with Liberase CI (Roche, Mannheim, 
Germany). This was done by dispensing 1 ml of digestion buffer (0.5 mg/ml Liberase 
CI in RPMI with 1% FBS, refer to Appendix I) to each spleen through three different 
puncture sites. The perfused spleens were then sliced into small pieces and incubated 
in digestion buffer for 30 min at 37 ºC. After incubation, the cells were meshed 
through a 70 µm cell strainer (BD) placed on top of a 50 ml falcon tube (BD). Cells 
collected in the falcon tube were washed with MACS buffer, resuspended in 10.88% 
optiprep solution (Sigma, refer to Appendix I) and layered with 2 ml of FBS. The cell 
suspension was then centrifuged at 1700 g for 10 min at 4 ºC without any acceleration 
or deceleration. Cells accumulating at the interface were harvested, washed with 
MACS buffer and magnetic labeled using CD11c microbeads. CD11c+ DC were 
positively selected by a MS column. 
 
2.18 Differentiation of dendritic cells from bone marrow 
Femur bones (with intact hip and knee joints) were dissected from euthanized Balb/C 
mice. Each bone was then scraped clean and sterilized in 70% alcohol. Under sterile 
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conditions, the two ends of the bone were snipped away and the bone marrow (BM) 
was flushed with PBS using a 10 ml syringe and 27 G needle (BD, NJ, USA). Bone 
marrow cells collected were passed through a 40 μm strainer (BD, NJ, USA), washed 
with PBS + 2 mM EDTA and centrifuged at 400 g for 10 min.  1 ml of RBC lysis 
buffer was added to resuspend the cell pellet followed by incubation for no more than 
1 min. The cells were then washed with PBS + 2 mM EDTA and resuspended in DC 
medium (refer to Appendix I) at a concentration of 1 × 106 cells/ml. The suspension 
fraction was discarded and culture medium was replaced with fresh DC medium at 
day 3. To induce maturation of DC, 1 µg/ml LPS (Sigma) was added to the culture at 
day 6 and the cells were harvested at day 7. 
 
The purity of splenic DC and bone marrow derived-DC was determined by flow 
cytometry using FITC-labeled anti-MHC-II and PE-labeled anti-CD11c antibodies 
(eBioscience). The maturation of DC was determined by testing the expressing of 
costimulatory molecules CD40, CD80 and CD86 (eBioscience). 
 
2.19 Generation of stable, CD137-expressing cell lines 
2.19.1 Plasmids 
The plasmid Mu_CD137_Neo was constructed by inserting full length mouse CD137 
cDNA into the eukaryotic expression vector pcDNA3.1(+) (Invitrogen, Carlsbad, CA) 
with a Neomycin resistance gene. The Mu_CD137_Zeo was constructed by inserting 
full length mouse CD137 cDNA into the eukaryotic expression vector 
pcDNA3.1/Zeo(+) (Invitrogen, Carlsbad, CA) with a ZeocinTM resistance gene. The 




Table 5. Primers for constructing expression vectors for CD137 protein. 
Primer Sequence Tm (ºC) 
muCD137_H_F 5’- tgt gca agc ttc gcc atg gga aac aac tgt tac aac -3’ 66 
muCD137_X_R 5’- ccc tcg agg gtc aca gct cat agc ctc ctc c -3’ 70 




The mouse melanoma cell line B16.F0 was transfected using LipofectamineTM 2000 
(Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. One day prior to 
transfection, 5 × 104 cells/well were plated in a 24-well plate (Nunc, Rosklide, 
Denmark). A DNA: Lipofectamine™ ratio of 1 μg : 2 μl was used. Cells were 
transfected either with the plasmid Mu_CD137_Neo, or with the empty vector as 
control. 
 
The mouse B cell lymphoma line A20 was transfected using Cell Line Nucleofector® 
Kits V from Amaxa (Lonza Cologne AG, Germany) following the manufacturer’s 
instructions. Cells were transfected either with the plasmid Mu_CD137_Zeo, or with 
the empty vector as control. Briefly, 2 × 106 cells were washed with PBS and 
resuspended in 100 µl Solution V. 2 µg of plasmid DNA was added into the cell 
suspension within 15 min and the mixture was transferred into an Amaxa certified 
cuvette. The cuvette was then placed into a nucleofector (Amaxa, Lonza Cologne AG, 
Germany) and subjected to nucleofector program L-13. Immediately after the 
program has finished, the cells were removed from the cuvette and transferred into a 




2.19.3 Measurement of membrane-bound CD137 expression on transfected cells 
48 h post-transfection, cells were washed twice with PBS and then detached using 10 
mM EDTA in PBS if necessary. 2 × 105 cells were stained with 50 μl of PE-
conjugated anti-mouse CD137 or with Hamster IgG isotype control antibodies for 30 
min at 4 ºC in dark. The antibodies were diluted in FACS buffer. After staining, cells 
were washed twice with FACS buffer and resuspended in 500 µl of buffer for analysis 
using Cyan™ flow cytometer (DakoCytomation, Denmark). Results were analysed 
with Summit 4.3 software (DakoCytomation, Denmark). 
 
2.19.4 Selection of stably-transfected clones 
48 h post-transfection, the transfected B16.F0 or A20 cells were transferred to 15 cm 
tissue culture dishes (BD Falcon™, Franklin Lakes, NJ), at a seeding density of 2.5 × 
105 cells/dish. Subsequently, the cells were maintained in their respective selection 
medium (refer to Appendix I) for approximately 14 days, with medium changes every 
3-4 days. Stable clones were picked when visible colonies of cells have formed in the 
culture dish. Although A20 is a suspension cell line, it too can form visible colonies 
like adherent cells during selection. Before picking the colonies, 24-well plates 
containing 400 μl of selection medium per well were prepared. Most of the medium 
was then aspirated from the culture dish containing the clones. Using a yellow pipette 
tip containing 100 μl of selection medium, the colony of interest was gently scraped, 
flushed with some medium and then aspirated. The cells were transferred to a well in 
one of the 24-well plates and the process was repeated until all the colonies were 
transferred in to 24-well plates. These cells were maintained with medium changes 




Clones transfected with CD137 were screened for CD137 expression via flow 
cytometry when they reached confluency (1-2 weeks after picking). The clones which 
expressed the desired levels of CD137 were subsequently expanded and named as 
‘B16/muCD137-clone number’ or ‘A20/muCD137-clone number’ respectively.  
 
Likewise, cells transfected with empty vector were subjected to the same selection 
procedure and clones were named as ‘B16/pcDNA-clone number’ or ‘A20/pcDNA-
clone number’ respectively. 
 
2.20 Measurement of cell viability by manual cell counting 
Cells were harvested after incubation with 10 mM EDTA for 10 min, centrifuged and 
resuspended in PBS. The numbers of viable cells were assessed by 0.4% Trypan blue 
(Sigma) staining and counted using a haemocytometer. 
 
2.21 Measurement of cell proliferation via 3H-thymidine incorporation 
Cells were pulsed overnight with 0.5 μCi of 3H-thymidine (diluted in medium) at 37 
ºC. Subsequently, the cells were harvested onto UniFilter plates (Perkin Elmer, 
Waltham, MA) using the MicroMate 196 cell harvester (Perkin Elmer, Waltham, MA). 
The filter plates were dried at 56 ºC for 1-2 h, after which 20 μl of MicroScint™ 
solution (Perkin Elmer, Waltham, MA) were added per well. Lastly, radioactivity was 





2.22 Lymphokine activated killer (LAK) cells assay for A20 cells 
LAK cells were prepared by culturing freshly isolated splenocytes at an initial cell 
density of 2 – 4 × 106 cells/ml, in the presence of 1000 U/ml of IL-2 (Proleukin, 
Norvatis Pharmaceuticals, East Hanover, NJ), for 4 to 5 days.  
 
On the day of the assay, required number of target cells were harvested and 
resuspended in PBS + 5% FBS (PBSF) at a concentration of 2 × 106 cells/ml. The 
cells were then fluorescence labeled by adding 30 µl/ml of Calcein AM (Molecular 
Probes, Invitrogen, Carlsbad, CA). Following a 20 min incubation at 37 ºC, cells were 
washed once with PBS and resuspended in PBSF at a final concentration of 1 × 106 
cells/ml. 100 µl of the target cells per well was then added into a round-bottomed 96 
well plate (Nunc, Rosklide, Denmark). 
 
During the labelling of target cells, the activated splenocytes were harvested, washed 
once with PBS, and resuspended in PBSF at the concentration of 1 × 106 cells/ml. 100 
μl of LAK cells/well were then added to the labeled target cells. For measuring the 
spontaneous and total lysis of target cells, 100 μl of PBSF or LAK lysis buffer (refer 
to Appendix I) instead of LAK cells were added respectively. Lysis of the cells was 
done at 37 ºC for 4 h, after which the plates were centrifuged at 1500 rpm for 10 min. 
Finally, 100 μl of supernatant from each well were transferred to a flat-bottomed 96 
well black plate (Nunc, Rosklide, Denmark), and fluorescence was measured at 
Ex485/Em535 using Tecan GENios plate reader (Tecan, Männedorf, Switzerland). 





Cytotoxicity (%) = 100 × (Sample lysis – Spontaneous lysis) 
Total lysis – Spontaneous lysis 
 
 
2.23 Coating of proteins or antibodies in tissue culture plate 
Recombinant proteins or monoclonal antibodies were diluted in PBS to a final 
concentration of 10 µg/ml (unless otherwise stated) and added to tissue culture plates. 
The volume of solution per well for different tissue culture plates were listed in the 
table below. Plates were incubated at 37 ºC for 2 h or 4 ºC overnight and the wells 
were washed 3 times with PBS before cells were added. 
 
2.24 Treatment of A20 cell with agonistic anti-CD137 antibodies 
Two monoclonal agonistic anti-CD137 antibodies and an isotype control antibody 
were used to treat A20/muCD137 cells. The antibodies were pre-coated on tissue 
culture plate as described in section 2.23. Alternatively, the antibodies were added 
into the culture in suspension. 1 × 106 cells/well were plated into a 6-well plate in the 
presence of the agonistic antibodies or the isotype control antibody. Photos of the 
cells were taken using Zeiss Axiovert 40 inverted microscope and attached Cannon 
digital camera (Zeiss, Göttingen, Germany) at time points of 24 h and 48 h. 
Supernatant from each treatment were harvested for cytokine measurement. 
 
2.25 Measurement of cytokine secretion by ELISA 
Several ELISA kits for mouse cytokines were purchased from different companies. 
The mouse IL-10 Duoset (31– 2000 pg/ml) and mouse IL-12p70 Duoset (39 - 2500 
pg/ml) were purchased from R&D systems. The murine IL-6 (63 – 4000 pg/ml) and 
IFN-γ (12 – 1500 pg/ml) ELISA development kits were purchased from PeproTech 
36 
 
(PeproTech Inc., Rocky Hill, NJ). The mouse IL-2 (2 – 125 pg/ml) and TNF-α (8 – 
500 pg/ml) ELISA kits were purchased from Biolegend and the mouse IL-4 (8 – 500 
pg/ml), IL-17 (8 – 500 pg/ml), IL-23 (63 – 4000 pg/ml) and TGF-β1 (125 – 8000 
pg/ml) ELISA Ready-Set-Go were purchased from eBioscience. All ELISAs were 
done according to the manufacturer’s protocols. Each sample was measured in 
duplicate. 
 
2.26 Nuclear Factor κB (NF-κB) Assay  
2 × 106 cells/well were plated in 6-well plates which was pre-coated with agonistic 
anti-CD137 antibody 158321 and Rat IgG2a control antibody. The cells were 
harvested 24 h later and the nuclear extracts were isolated using Nuclear Extract Kit 
(Active Motif, USA). A Bradford assay was done using Bio-Rad Protein Assay (Bio-
Rad, USA) to determine the concentrations of proteins obtained. Normalized nuclear 
extract samples were then subjected to NF-κB Assay according to the protocol of the 
TransAMTM NF-κB Family Transcription Factor Assay Kit (Active Motif, USA). 
 
2.27 Induction of subcutaneous tumor in syngeneic mouse models 
In order to evaluate the in vivo anti-tumor effect of CD137, two syngeneic mouse 
models were used by subcutaneous injection of stably transfected A20 cells into 
Balb/C mice and B16.F0 cells into C57/Bl6 mice respectively. B16/muCD137 or 
B16/pcDNA cells were washed twice with PBS and then detached using 10 mM 
EDTA in PBS. A20/muCD137 or A20/pcDNA cells were washed twice with PBS in 
tubes. All cells were then resuspended in PBS at a concentration of 1 × 106 cells/ml 
and placed on ice before injection. 4 to 10 mice per group were anaesthetized by intra-
peritoneal injection of 5 mg/kg of Xylazine (AHU, NUS) and the hair of the right 
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flank of each mouse was shaved for better visualization of the tumors. 200 µl of cell 
suspension was then injected into the right flank of the mouse subcutaneously. 
 
The presence of tumor in each mouse was observed every other day and the sizes of 
the tumors were recorded using ABS digimatic caliper (Mitutoyo, Japan). Once the 
tumor of any mouse in the group exceeded 1cm in diameter, all the mice were 
sacrificed. Blood of the mice was collected via cardiac puncture. Tumors and spleens 
were isolated from mice, measured for weights, then fixed in paraformaldehyde and 
embedded in paraffin for histological analysis.  
 
2.28 Statistics 
Data are expressed as means ± standard deviation (SD) of the indicated numbers of 
experiments. Statistical significance was determined by the two-tailed Student's t-test. 
38 
 
CHAPTER 3 RESULTS 
In order to characterize the potential antagonistic role of soluble CD137 on 
membrane-bound CD137, the generation and expression of soluble CD137 will be 
investigated first in splenocytes and certain types of immune cells. The expression 
kinetics of soluble and membrane-bound CD137 will be compared in each cell type. 
This will be followed by an investigation of the antagonistic mechanism of soluble 
CD137 by testing the multimeric structure of soluble CD137 and its binding capacity 
to CD137L. In addition, the role of soluble CD137 in regulating immune responses 
will be addressed by investigating a potential correlation of soluble CD137 with 
certain immune activation status such as AICD. And more importantly, possible 
functions of soluble CD137 in regulating cytokine secretion will be examined by 
depleting soluble CD137 in vitro. After characterizing its expression, antagonistic 
mechanism and function, the correlation of soluble CD137 with murine disease 
models will be studied. Lastly, the possible role of CD137 in promoting tumorigenesis 
will be investigated.  
 
3.1 Generation of murine soluble CD137 
Soluble CD137 was first identified in mouse in 1995 when Serateh et al. (1995) 
identified two spliced forms of CD137 mRNA in activated splenocytes and 
thymocytes (Setareh et al., 1995). Subsequent studies in man have identified human 
soluble CD137 and characterized it as an antagonist of membrane-bound CD137 
(Michel and Schwarz, 2000). Several groups have shown the correlation of soluble 
CD137 with human diseases such as autoimmune diseases and cancers (Jung et al., 
2004; Michel et al., 1998; Furtner et al., 2005). Compared to abundant publications on 
soluble CD137 in human system, the only report showing the existance of murine 
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soluble CD137 protein was from Wilcox et al. (2002) who found the secretion of 
soluble CD137 from mouse DC (Wilcox et al., 2002). However, no experiment was 
done to characterize the secreted soluble CD137 in that study. In order to conduct a 
comprehensive characterization of murine soluble CD137, the expression of soluble 
CD137 will first be confirmed in splenocytes at both mRNA and protein levels. This 
will be followed by a study of the source of soluble CD137. Briefly, different types of 
immune cells such as T cells and DC will be isolated and screened for expression of 
soluble CD137. The expression profile of soluble CD137 and membrane-bound 
CD137 will be compared in each cell types. 
 
3.1.1 Soluble CD137 is secreted by activated splenocytes 
In order to characterize expression of murine soluble CD137, splenocytes were used 
to test the presence of soluble CD137 since the spleen contains most types of immune 
cells. Another reason for using splenocytes was that soluble CD137 mRNA has been 
detected in activated splenocytes previously (Setareh et al., 1995). Splenocytes 
isolated from a Balb/C mouse and a C57/Bl6 mouse were activated with Con A, PMA 
+ A23187, PHA, anti-CD3 antibody or IL-2 for 24, 48 or 72 h. The concentrations of 
stimuli used are listed in Table 6. Supernatant of the culture were collected at 
indicated time points and the presence of soluble CD137 were tested by ELISA.  
 
As shown in Figure 4, unstimulated cells did not secrete soluble CD137 but 
supernatants from all activated cells contained soluble CD137. Highest soluble 
CD137 levels were obtained after stimulation of the cells with Con A or immobilized 
anti-CD3 antibody. In addition, between the two mouse strains used, levels of soluble 




Table 6. Stimuli used for splenocytes activation. 
Stimulus  Abbrev. Conc. Source  
Concanavalin A  Con A 5 µg/ml Sigma 
Phytohemagglutinin PHA 5 µg/ml Sigma 
Phorbol 12-myristate 13-acetate PMA 10 ng/ml Sigma 
Calcium Ionophore A23187 A23187 100 nM Sigma 
Recombinant human IL-2, Proleukin IL-2 1000 U/ml Chiron 
Anti-CD3 antibody, immobilized Anti-CD3 10 µg/ml  eBioscience 
 
 
soluble CD137 varied from 0.1 ng/ml to 17 ng/ml among stimuli, its expression 
kinetics were comparable. An increase of soluble CD137 levels over time was 
observed with all stimuli used. These data indicate that soluble CD137 can be induced 
by various stimuli and is not strain-specific. For the subsequent experiments, 
splenocytes from Balb/C mice were used. And Con A was used to induce expression 
of soluble CD137 unless otherwise stated. 
 
Expression of soluble CD137 was compared to that of membrane-bound CD137. 
Splenocytes from Balb/C mice were cultured in vitro at a concentration of 3 × 106 
cells/ml and stimulated with 5 µg/ml Con A. The cells were cultured for up to 5 days 
and analyzed at time points of 6 h, 12 h, 24 h, 48 h, 72 h, 96 h and 108 h. At each time 
point, cells were harvested, stained for membrane-bound CD137 and fixed with 1% 
paraformaldehyde for flow cytometry analysis. Culture supernatants were also 




The results show that the expression for both membrane-bound and soluble CD137 
was strictly activation-dependant, as resting splenocytes did neither express 
membrane-bound nor soluble CD137. Membrane-bound CD137 expression could be 
detected as early as 6 h by flow cytometry on 12% of the cells. Expression peaked at 
48 h with 68% of the cells staining positive for CD137, and declined to 13% positive 
cells at days 4 and 5 (Figure 5A, 5B). Expression of soluble CD137 was not 
detectable until 24 h. It increased sharply between 24 and 48 h, in parallel with 
membrane-bound CD137 expression. However, while membrane-bound CD137 
expression dropped, soluble CD137 levels remained high and did not change until day 
5 (Figure 5C). These data suggest that expression of soluble CD137 slightly lags 
behind expression of membrane-bound CD137, which indicates that soluble CD137 is 
not a mere by-product from shedding of membrane-bound CD137.   
 
In order to assess whether the elevated soluble CD137 level from day 2 onwards 
reflected its former release or whether they were subject to a turnover and were 
continuously replaced, we tested the in vitro stability of soluble CD137. Cell culture 
supernatant containing 800 pg/ml of soluble CD137 was incubated for 7 days at 37 ºC 
and aliquots were collected daily, frozen and analyzed together at the end of the 
experiment at day 7. There was no decline in soluble CD137 levels suggesting that 
soluble CD137 does not degrade (Figure 6). This result implies that the elevated 
levels at days 3, 4 and 5 in Figure 5C may be a tissue culture artefact due to the 







Figure 4. Induction of soluble CD137 expression. Splenocytes at a concentration of 
3 × 106 cells/ml were activated with ConA (5 µg/ml), PMA (10 ng/ml) + A23187 
(100 nM), PHA (5 µg/ml), anti-CD3 (10 µg/ml immobilized) or IL-2 (1000 U/ml) for 
24, 48 or 72 h. Concentrations of soluble CD137 were determined by ELISA. 
Depicted are means ± SD of duplicate measurements. This data is representative of 







Figure 5. Time course of CD137 expression. Splenocytes at a concentration of 3 × 
106 cells/ml were activated with 5 µg/ml of Con A. (A) After indicated time periods 
expression of membrane-bound CD137 was determined by flow cytometry and the 
percentages of CD137 positive cells were summerized in (B). (C) Concentrations of 
soluble CD137 of conditions in (A). Depicted are means ± SD of triplicate 




Figure 6. In vitro stability of soluble CD137. Supernatant of ConA-activated 
splenocytes was incubated at 37 ºC. Aliquotes were sampled every 24 h and tested by 
ELISA. Depicted are means ± SD of triplicate measurements. This experiment was 
performed three times with identical results. 
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A RT-PCR test was done to compare the expression of soluble CD137 and 
membrane-bound CD137 at mRNA levels. Total RNA was extracted from activated 
splenocytes and reverse transcribed to cDNA. PCR was performed using cDNA of 
these cells as template. The primer pair muCD137_F/muCD137_R was designed to 
amplify the full length CD137 cDNA, which is 768 bp. The PCR reaction mix and 
thermal cycling programs for amplifying murine CD137 and the internal control 
GAPDH are listed in Table 2 and Table 3 respectively in charpter 2. Two PCR 
products were obtained with cDNA from activated splenocytes (Figure 7). The larger 
768 bp product corresponds to the size expected on the basis of the sequence for the 
membrane-bound CD137. The second PCR product, which is 135 bp shorter, 
represents soluble CD137 without the transmembrane domain. The expression 
kinetics of the two mRNA isoforms were identical. Both membrane-bound and 
soluble CD137 became detectable as early as 16 h and peaked at 48 h. The decrease 
of soluble CD137 mRNA from 48 h to 96 h indicates once again that the elevated 




Figure 7. Splenocytes express two forms of CD137 mRNA. Splenocytes were 
harvested from Balb/C mice. Total RNA was isolated from naïve, Con A-stimulated 
splenocytes at 16, 48 and 96 h. Total RNA was reverse transcribed using M-MuLV 
reverse transcriptase (Fermentas), followed by PCR for CD137. The PCR products 
were separated on 1% agarose gels and visualized by ethidium bromide staining. This 




3.1.2 Soluble CD137 is released by T cells 
Splenocytes are a heterogeneous mixture of cells which contains T cells, B cells, DC, 
macrophages, NK cells and granulocytes. To determine from which subpopulation of 
cells soluble CD137 is produced, different types of immune cells were isolated and 
tested for the presence of soluble CD137. T cells were chosen as prime candidates as 
anti-CD3 antibody has been shown to have the largest effect on the induction of 
soluble CD137 (Figure 4).  
 
Helper and cytotoxic T cells were isolated from Balb/C splenocytes using magnetic 
beads coupled to antibodies specific for CD4 and CD8, respectively. The isolated 
cells were incubated with 5 µg/ml Con A to test the expression of membrane-bound as 
well as soluble CD137. Upon activation CD4+ as well as CD8+ T cells started to 
express CD137 on the surface. Expression kinetics was similar for CD4+ and CD8+ T 
cells and maximum CD137 expression was found at 48 h (Figure 8A and B). 
However, levels of CD137 expression were significantly higher on CD8+ compared to 
CD4+ T cells, especially at the earlier time points of 24 and 48 h.  
 
Soluble CD137 was also produced by both CD4+ and CD8+ T cells upon activation. 
Interestingly, levels of soluble CD137 were slightly higher in CD4+ T cells even 
though expression of membrane-bound CD137 was significantly higher in CD8+ T 
cells (Figure 8C). The differential expression of soluble and membrane-bound CD137 
in the two subtypes of T cells resulted in a significant higher soluble to membrane-
bound CD137 ratio in CD4+ T cells as compared to CD8+ T cells, indicating that 
CD8+ T cells were more likely to be the target of soluble CD137 as an antagonists of 




In both cell populations soluble CD137 levels increased during the culture period with 
highest levels at day 4. However, as mentioned above this continuous increase in 
soluble CD137 may be a tissue culture artefact as in vivo soluble CD137 gets likely 
removed from the circulation. Indeed, as shown by RT-PCR, the expression kinetics 
of the mRNA isoforms encoding soluble and membrane-bound CD137 were identical. 
Both peaked at days 2 – 3, and were much reduced on day 4 (Figure 9).  
 
Results shown here indicate that T cells can be a main source of soluble CD137 as T 
cells produce comparable levels of soluble CD137 as total splenocytes. Expression 
levels of soluble CD137 in CD4+ and CD8+ T cells were comparable. However, the 
significantly higher levels of membrane-bound CD137 in CD8+ T cells makes them 






Figure 8. CD137 is expressed by activated T cells. CD4+ or CD8+ T cells at a 
concentration of 2 × 106 cells/ml were activated with 5 µg/ml Con A for indicated 
periods of time. (A) Expression of membrane-bound CD137 was determined by flow 
cytometry. Black empty curve: isotyp; red filled curve: anti-CD137. (B) Quantitative 
depiction of data in (A). (C) Concentrations of soluble CD137 were determined by 
ELISA. Depicted are means ± SD of triplicate measurements. (This experiment was 





Figure 9. Expression of CD137 mRNA isoforms by T cells. Messenger RNA 
expression of CD137 isoforms in Con A stimulated CD4+ and CD8+ cells were 
determined by RT-PCR. A GAPDH fragment was amplified to verify comparable 
amounts of template. PCR products were analyzed on a 1% TAE agarose gel and 




3.1.3 Expression of soluble CD137 by regulatory T cells 
CD4+CD25+ Treg from mouse have been reported previously to express membrane-
bound CD137 (Choi et al., 2004). We have shown earlier that soluble CD137 is 
produced by CD4+ T cells. It is highly likely that Treg also express soluble CD137 as 
they are a subset of CD4+ T cells.  
 
Regulatory T cells were isolated from mouse spleens using CD4+CD25+ Regulatory T 
Cell Isolation Kit (Miltenyi Biotec) following the manufacturer’s instructions. Briefly, 
CD4- cells were depleted from freshly isolated splenocytes by a cocktail of antibodies 
against an array of antigens that are not expressed on CD4+ T cells. CD25+ cells were 
then positively selected from the CD4+ fraction by labeling with a PE-conjugated 
CD25 antibody follwed by anti-PE microbeads. In this case, the selected CD4+CD25+ 
cells were PE-labelled. These cells were immediately activated by adding anti-CD3 
antibody together with IL-2 and incubated for 24, 48 and 72 h in vitro. To detect 
membrane-bound CD137, the cells were stained with biotinylated anti-CD137 
antibody (clone 17B5), followed by Streptavidin-APC. The cells were then analyzed 
by flow cytometry with PE-labelled anti-CD25 and APC-labelled anti-CD137 
respectively.  
 
Expression of membrane-bound CD137 on CD4+CD25+ Treg was compared with that 
on CD4+CD25- and that on total CD4+ cells. Percentages of CD137-positive cells 
were counted in the APC+PE- region for CD4+CD25- cells, and in the APC+PE+ 
region for CD4+CD25+ cells. For total CD4+ cells, cells in both the APC+PE- and the 
APC+PE+ regions were counted as CD137-positive. The result from flow cytometry is 
shown in Figure 10A and the percentage of CD137-positive cells in each population is 
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summarized in Figure 10B. There was no detectable expression of membrane-bound 
CD137 at 24 h in all three cell populations tested (Figure 10A and 10B). All cell 
populations had the peak expression of CD137 at 48 h, with 33.9%, 27.8% and 41.0% 
for CD4+, CD4+CD25- and CD4+CD25+ cells, respectively. And the percentage of 
CD137-expressing cells in these three populations dropped to 19.3%, 22.6% and 
30.5%, respectively, at 72 h. The expression levels of CD137 in Treg were the highest 
among the three populations at both 48 h and 72 h. This was probably due to the 
addition of IL-2 to the culture. CD25 is the alpha chain of the IL-2 receptor that 
associates with CD122 to form a heterodimer that can act as a high affinity receptor 
for IL-2. Treg could get additional activation signals from IL-2 receptor as compared 
to CD25- T cells. Thus, a higher expression of membrane-bound CD137 was observed.  
 
Expression of soluble CD137 was also detected in Treg. The expression kinetics of 
soluble CD137 in Treg was similar to the other two populations, with the highest level 
obtained at 72 h. However, levels of soluble CD137 secreted by Treg were much 
higher than that by total CD4+ cells or by CD4+CD25- T cells. This could be again due 
to the addition of IL-2 (Figure 11).  
 
In summary, like the other subsets of T cells, Treg expressed soluble CD137 upon 
activation. When IL-2 was added into the culture, both membrane-bound and soluble 








Figure 10. Expression of membrane-bound CD137 by different subsets of CD4+ 
T cells. CD4+, CD4+CD25- and CD4+CD25+ T cells at a concentration of 106 cells/ml 
were activated with 10 µg/ml anti-CD3 antibody and 1000 U/ml IL-2 for indicated 
periods of time. (A) Expression of membrane-bound CD137 was determined by flow 
cytometry. (B) Quantitative depiction of data in (A).This experiment was performed 






Figure 11. Expression of soluble CD137 by different subsets of CD4+ T cells. 
CD4+, CD4+CD25- and CD4+CD25+ T cells at a concentration of 106 cells/ml were 
activated with 10 µg/ml anti-CD3 antibody and 1000 U/ml IL-2 for indicated periods 
of time. Expression of soluble CD137 was determined by ELISA. Means ± SD of 







3.1.4 Expression of soluble CD137 by DC 
DC is the only cell type that has been shown previously to express both soluble and 
membrane-bound CD137 at protein levels (Futagawa et al., 2002; Wilcox et al., 2002). 
However, the correlation between the expression of membrane-bound and soluble 
CD137 in DC remained unclear. In order to get a comprehensive understanding of 
CD137 expression in DC, both splenic DC and bone marrow-derived DC (BMDC) 
were included in the experiment.  
 
Expression of CD137 was first analyzed in splenic DC. To achieve high purity of DC 
from spleen, single-cell suspensions were prepared by Liberase CI digestion. The 
cells were then seperated by centrifugation in 10.88% Optiprep solution (Sigma). 
Cells accumulated at the interphase were recovered and labelled with CD11c 
microbeads (Miltenyi). CD11c+ DC were positively isolated by magnetic sorting. The 
freshly isolated DC were cultured in vitro and matured by addition of 1 µg/ml LPS. 
 
The purity of splenic DC was evaluated by the double staining of CD11c and MHC-II 
on freshly isolated DC. As shown in Figure 12A, 97.4% of the cells isolated were 
double positive for CD11c and MHC-II, indicating that the cells isolated from spleen 
were pure DC. Expression of CD137 and CD137L was analyzed at 24 and 48 h on 
both immature and mature DC (Figure 12B). Staining for the costimulatory molecules 
CD80 and CD86 was also included to ensure a successful maturation of DC. Results 
show that addition of LPS to DC induced upregulation of CD80 and CD86, which 
indicates maturation of the cells. However, neither CD137 nor CD137L could be 
detected on the cell surface at all four conditions (Figure 12B). This result was 
compared with previously published data on the expression of CD137 in DC. For 
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CD137 staining, Wilcox (2002) chose a biotinylated monoclonal anti-CD137 antibody 
2A followed by streptavidin-PE (Wilcox et al., 2002). The use of streptavidin-biotin 
may be able to increase the sensitivity of staining because one biotin is able to bind to 
4 streptavidin molecules thereby amplifying the signal. Another study done by 
Futagawa et al. (2002) used a monoclonal antibody 1AH2 to stain CD137 on DC 
(Futagawa et al., 2002). However, as we tested earlier on CD137-transfected cell lines, 
1AH2 can only achieve 70% of the staining given by 17B5, the antibody used for 
staining of CD137 throughout this project (data not shown). One consistant result 
among different studies is that the expression of CD137 on DC is not as prominent as 
on T cells. It was also mentioned that expression of CD137 on the surface of DC can 
be influenced by the different methods for isolating DC (Wilcox et al., 2002). A more 
sensitive method will be needed to detect membrane-bound CD137 on DC. 
 
Expression of soluble CD137, however, was able to be detected from DC cultures 
(Figure 13).  Splenic DC started to secrete low levels (4.9 ± 2.7 pg/ml) of soluble 
CD137 during the first 24 h of culture, and the addition of LPS increased soluble 
CD137 level to 29.2 ± 3.3 pg/ml. Culture for another 24 h significantly increased 
soluble CD137 levels to 160.2 ± 18.5 pg/ml and no remarkable difference could be 
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Figure 12. Flow cytometry analysis of splenic DC. 106/ml DC isolated from spleen 
were cultured with or without LPS for 48 h. Purity of freshly isolated DC was 
evaluated by double staining for CD11c and MHC-II (A). Expression of CD80, 
CD86, CD137 and CD137L of DC was determined by staining the cells with PE-
conjugated antibody followed by flow cytometry (B). This experiment was performed 






Figure 13. Expression of soluble CD137 by splenic DC. 106/ml DC isolated from 
spleen were cultured with or without LPS for 48 h. Supernatants of DC culture were 
harvested at 24 and 48 h and presence of soluble CD137 was tested by ELISA. Means 







To generate BMDC in vitro, total bone marrow cells were cultured in the presence of 
GM-CSF and IL-4 for 7 days. LPS was added to the culture at day 6 to induce 
maturation of DC. The purity of BMDC was determined by double staining for 
CD11c and MHC-II on day 7. Expression of costimulatory molecules CD80 and 
CD40 on the cells was also analyzed in order to evaluate the effect of LPS-induced 
maturation. As shown in Figure 14A, the purity of BMDC was not as high as that of 
isolated splenic DC, with only 63.1% of the cells staining double positive for CD11c 
and MHC-II. Addition of LPS increased the percentage of double positive cells to 
70.2%. These cells represented a typical DC phenotype as shown by the upregulation 
of CD80 and CD40 upon maturation (Figure 14B). CD137L was once again absent on 
both immature and mature cells, however, expression of membrane-bound CD137 
became detectable. There were 8.0% of the immature cells and 17.9% of the mature 
cells expressing membrane-bound CD137. 
 
Levels of soluble CD137 were tested in BMDC cultures at different time points. It 
was found that BMDC produce significantly higher levels of soluble CD137 than 
splenic DC (Figure 15). Levels of soluble CD137 released from BMDC were 20 times 
higher than those produced by splenic DC. The production of soluble CD137 was 
continuous since abundant soluble CD137 can be detected even after medium 
replacement on days 3 and 6. The addition of LPS did not increase soluble CD137 
levels, unlike that of membrane-bound CD137, indicating that in DC expression of 
soluble CD137 does not correlate with membrane-bound CD137.  
 
In summary, soluble CD137 is produced by both splenic DC and BMDC cultures in 
vitro. Maturation of DC does not increase levels of soluble CD137. Expression of 
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membrane-bound CD137 can only be detected in BMDC and can be upregulated by 

















Figure 14. Flow cytometry analysis of BMDC. 106/ml total bone marrow cells were 
cultued with 40 ng/ml GM-CSF + 25 ng/ml IL-4 for 7 days with medium changes 
every 3 days. BMDC were matured by 2.5 µg/ml LPS on day 6, and subjected to flow 
cytometric analysis on day 7. The purity of generated BMDC was evaluated by 
double staining for CD11c and MHC-II (A). Expression of CD80, CD40, CD137 and 
CD137L on DC was determined by staining the cells with PE-conjugated antibodies 







Figure 15. Expression of soluble CD137 by BMDC. 106/ml total bone marrow cells 
were cultued with 40 ng/ml GM-CSF + 25 ng/ml IL-4 for 7 days with medium change 
every 3 days. BMDC were matured by 2.5 µg/ml LPS on day 6. Supernatants of 
BMDC culture were harvested at days 3, 5, 6 and 7 and the presence of soluble 
CD137 was tested by ELISA. Means ± SD of triplicates are depicted. This experiment 
was performed two times with identical results. 
 
 
3.1.5 Summary  
In this section, the expression of soluble CD137 was examined in various cell types 
including splenocytes, effector T cells, cytotoxic T cells, Treg and DC. Expression of 
soluble CD137 is activation dependent in all T cell types. Expression levels of soluble 
CD137 seem to correlate with membrane-bound CD137 in most cases except for DC. 
Maturation of DC increases membrane-bound but not soluble CD137 expression. The 
diverse expression profiles of soluble CD137 in different cell types indicates that 
soluble CD137 might be involved in multiple immune responses exerted by different 




3.2 Potential agonistic function of murine soluble CD137 
Members of the TNF and TNF receptor families exist as trimers and depend on 
trimerization for binding and functional activities (Idriss and Naismith, 2000). One of 
the best-studied cases is CD40 ligand (CD154), which is able to costimulate B cell 
proliferation in its trimeric but not monomeric form (Fanslow et al., 1994). Hence, the 
function of soluble CD137 could be dependent on its multimeric status.  
 
As discussed earlier, there are two potential mechanisms to explain the antagonisic 
function of soluble CD137. The first one is that soluble CD137 may bind to CD137L 
and compete with membrane-bound CD137 for the binding sites of CD137L (Figure 
3B). The other explanation is that soluble CD137 could insert into existing 
membrane-bound CD137 trimers (Figure 3C). And because soluble CD137 lacks the 
cytoplasmic domain, the soluble CD137 inserted trimers can not transduce signals. 
The multimeric status of soluble CD137 can be crucial to determine which 
mechanism is utilized by soluble CD137 to carry out its antagonistic functions. The 
trimeric soluble CD137 should be able to bind to CD137L while the monomeric form 
is more likely to insert into existing membrane-bound CD137 trimers. 
 
In order to determine the multimeric status of soluble CD137, the size of CD137 was 
evaluated by Western blot and size exclusion chromatography (SEC) analysis.  
 
3.2.1 Examination of the size of soluble CD137  
Murine soluble CD137 is generated by gene differential splicing. Soluble CD137 is 
encoded by a mRNA splice variant lacking the transmembrane domain because of the 
deletion of exon 8 (Setareh et al., 1995). Soluble CD137 consists of 211 aa, which 
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predicts a molecular weight of 22.46 kDa for soluble CD137 monomer. However, the 
actual size of proteins may be different from the predicted size because of post-
transcriptional modifications such as glycosylation. Indeed, protein sequence analysis 
demonstrates that soluble CD137, as same as membrane-bound CD137, has two 
potential N-glycosylation sites (Asn-X-Ser/Thr, X ≠ Pro) in its extracellular domain. 
Therefore, the size of CD137 monomer was first examined by Western blot analysis.  
 
CD137-expressing A20/muCD137 cells or control A20/pcDNA cells were used for 
the determination of the actual size of CD137. These cells were generated by stable 
transfection which will be discussed later. The cells were lysed with RIPA buffer for 
30 minutes at 4ºC and the cell lysates were loaded into 12% SDS-PAGE gel followed 
by electrophoresis. The presence of CD137 was then detected by biotinylated anti-
CD137 antibody and the size of CD137 was compared to the protein standard 
(Fermentas). As shown in Figure 16, a single band was detected at the size of 40 kDa, 
which corresponding to a CD137 monomer. Compared to the predicted size of 
membrane-bound CD137, which is 26 kDa, the difference in predicted and actual size 
is likely due to glycosylation. The size of soluble CD137 could be slightly smaller 





The multimeric status of soluble CD137 in splenocyte supernatant was then 
determined by SEC. In a standard SEC protocol to determine protein size, purified 
protein will need to be loaded onto a column. The size of protein will be determined 
by comparing the elution volume of protein of interests to that of a number of proteins 
with known sizes. However, the purification of soluble CD137 could be difficult and 
tedious. Hence, an alternative but simpler method was used to evaluate the size of 
soluble CD137. Briefly, soluble CD137 together with other proteins in the supernatant 
were loaded onto a SEC column and the eluent from the column was collected in 
multiple small fractions. Instead of reading absorbance at 280 nm (conventional 
method) the elution profile of soluble CD137 was determined by testing the presence 
of soluble CD137 in each elution fraction by ELISA. To ensure that the 
concentrations of fractionated soluble CD137 were high enough to be detected by 
 
Figure 16. Determination of the size of membrane-bound CD137 by Western 
blot. A20 cells transfected with CD137 expression vector of control vector were lysed 
and the cell lysated were used for western blot analysis. Protein standards (Bio-Rad) 
with indicated sizes were used to determine the band size of CD137 protein.  
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ELISA, soluble CD137-containing supernatant was concentrated for 40-fold before 
loading onto the column. Proteins of known sizes were used for calibration of the 
column by the reading of absorbance at 280 nm. These proteins included Glutamate 
Dehydrogenase (290 kDa), Lactate Dehydrogenase (142 kDa), enolase (67 kDa), 
myokinase (32 kDa) and cytochrome C (12.4 kDa).  
 
As shown in the upper panel of Figure 17A, the five standard proteins were well 
separated by the column. Based on the size and elution volume of each protein 
standard, a standard curve was generated in Figure 17B. Hence, the size of an 
unknown protein can be calculated according to the equation y=52895e-0.47x. 
 
The lower panel of Figure 6 shows that no soluble CD137 could be detected below 
enolase, the 67 kDa size standard arguing against the occurrence of soluble CD137 as 
dimers or monomers. Soluble CD137 was eluted in two peaks, one in the 11.2 ml and 
the other in the 13.2 ml fraction. The calculated molecular weights for these two 
fractions are 271 and 108 kDa, respectively (Figure 17B). The 108 kDa peak 
represents a soluble CD137 trimer. The 271 kDa peak may represent a higher order 
multimer of soluble CD137. This result shows that soluble CD137 in the culture 
supernatant may exist as a trimer or a higher order multimer. 
 
An alternative explanation for the high molecular weight of soluble CD137 would be 
the existence of soluble CD137 and soluble CD137L complexes. To exclude this 
possibility, we tested the presence of a CD137/CD137L complex in the culture 
supernatant. In this experiment, different combinations of anti-CD137 and anti-
CD137L antibodies were used as capture and detection antibodies in a sandwich 
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ELISA format. Soluble CD137-containing supernatant was then added as sample and 
detected by a standard sandwich ELISA protocol. Recombinant CD137-Fc and 
CD137L-FLAG proteins were added as positive controls. The combinations of 
capture and detection antibodies included (i) anti-CD137 capture paired with anti-
CD137 detection antibodies, (ii) anti-CD137L capture paired with anti-CD137 
detection antibodies, (iii) anti-CD137 capture paired with anti-CD137L detection 
antibodies and (iv) anti-CD137L capture paired with anti-CD137L detection 
antibodies. If a soluble CD137/CD137L complex exists in the supernatant, it should 
be detectable by combination (ii) or (iii). The presence of soluble CD137 or CD137L 
along could be detected by combination (i) and (iv) respectively. However, as shown 
in Figure 18, we could not detect any soluble CD137L in the supernatant under all 
four experimental conditions, indicating that even soluble CD137L alone was not 
present in the supernatant. Soluble CD137 could only be detected when anti-CD137 
antibodies were used as both capture and detection antibody (combination i). The 
absence of soluble CD137/CD137L complexes could be the reason why there was no 
soluble CD137 in other combinations of the antibodies. This result indicates that the 








Figure 17. Calculation of the size of soluble CD137 by SEC. (A) Cell culture 
supernatant was concentrated 40-fold and fractionated by SEC. Individual fractions 
were tested for the presence of soluble CD137 by ELISA. Proteins of known sizes 
were used for calibration of the column. mAU: milli-absorbance units at 280 nm. (B) 
The molecular weights of standard proteins were plotted against their elution 






Figure 18. Detection of soluble CD137 and CD137L complexes. Cell culture 
supernatant was analyzed for the presence of soluble CD137-CD137L complexes. 
Anti-CD137 or anti-CD137L antibodies were used as capture and detection 
antibodies in a sandwich ELISA. Recombinant CD137 and CD137L proteins were 






3.2.2 Soluble CD137 can bind to CD137L 
Results from Western blot and SEC analysis indicate that naturally produced soluble 
CD137 exits as a trimer or a higher order multimer. As discussed earlier, a monomeric 
form of soluble CD137 may insert into existing membrane-bound CD137 trimers, 
while multimeric soluble CD137 was more likely to bind to CD137L. In order to 
assess how soluble CD137 might be able to influence activities of the CD137 
receptor/ligand system, the binding capacity of soluble CD137 to CD137L was tested.  
 
The experiment was done by replacing the capture antibody in the soluble CD137 
ELISA by a recombinant FLAG-tagged CD137L protein or by a FLAG control 
protein. Soluble CD137-containing supernatant from activated splenocytes culture 
was then added into the pre-coated ELISA plates and presence of CD137 was 
detected by an anti-CD137 detection antibody. The anti-CD137 capture antibody was 
also included as a positive control for the ELISA. As shown in Figure 19, the 
CD137L-FLAG protein was able to bind to soluble CD137 in the cultured supernatant 
and to CD137-Fc protein which was included as a positive control. The FLAG control 
protein bound to neither one (Figure 19). This result clearly shows that soluble CD137 
was able to bind to CD137L recombinant protein. The CD137L protein exhibited a 
reduced binding affinity to soluble CD137 and to CD137-Fc compared to the anti-






Figure 19. Determination of the binding of soluble CD137 to recombinant 
CD137L. Cell culture supernatant from Con A-activated splenocytes were measured 
by traditional ELISA (α-CD137) or in a modified form in which the capture antibody 
has been replaced by a CD137L-FLAG or a FLAG control protein. No protein (PBS), 
Fc or CD137-Fc proteins were included as negative and positive controls, 
respectively. Means ± SD of triplicates are depicted. *p < 0.05; **p < 0.01. 
 
 
The binding capacity of soluble CD137 to cell surface expressed CD137L was also 
evaluated. In this experiment, a mouse B cell lymphoma line, A20, which expresses 
endogenous CD137L was used to provide CD137L (Figure 20A). Soluble CD137-
containing supernatant was first concentrated 40 times using an Amicon ultra 
centrifugal filter unit 10 kDa (Millipore, Billerica, MA, USA) which is a tube filter 
that only retains protein with sizes of 10 kDa and above during centrifugation. The 
concentration of soluble CD137 in the supernatant was successfully increased from 20 
ng/ml to 800 ng/ml as determined by ELISA (Figure 20B). Concentrated supernatant 
was then serially diluted to test the binding efficiency of soluble CD137 to CD137L. 
After incubation with CD137L-expressing A20 cells for 16 h, levels of soluble 
CD137 in the supernatant were tested by ELISA. As shown in Figure 20C, soluble 
CD137 in all dilutions was effectively depleted after incubation with CD137L-
expressing A20 cells. The effect of depletion was most significant with the highest 
concentration of soluble CD137 used, with a decrease of soluble CD137 concentration 
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from 250 ng/ml to less than 50 ng/ml. This result indicates that soluble CD137 can 
bind to cell surface expressed CD137L as well.  
 
The results obtained from both recombinant CD137L protein and cell surface 
expressed CD137L demonstrate that soluble CD137 can bind to CD137L. This also 
provides evidence that by competitively binding to CD137L, soluble CD137 may be 
able to interfere with the interaction of membrane-bound CD137 and CD137L and 






Figure 20. Determination of the binding of soluble CD137 to cell surface 
CD137L. (A) Expression of CD137L by A20 cells. (B) 4 ml of soluble CD137-
containing supernatant were concentrated to 100 µl by centrifugation through an 
Ultra-4 centrifugal filter unit (Amicon) at 7500g for 15 min. The effect of 
concentrating was evaluated by ELISA. (C) Concentrated supernatant was serially 
diluted with medium. 500 µl of diluted supernatant were incubated with 106 A20 cells 
per well in a 24 well tissue culture plate for 16 h. Soluble CD137 in the supernatant 
before (control) and after the incubation was tested by ELISA. Means ± SD of 
triplicates are depicted. 
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3.3 Regulatory function of murine soluble CD137 
Expression of soluble CD137 has been shown in different types of immune cells by us 
as well as by other groups (Setareh et al., 1995; Wilcox et al., 2002). However, the 
functional study on soluble CD137 was very limited. Although soluble CD137 has 
been shown to antagonize membrane-bound CD137 and to abolish CD137 mediated-
immune responses (DeBenedette et al., 1995; Hurtado et al., 1995), the use of 
recombinant CD137 protein instead of endogenous soluble CD137 does not 
adequately reflect the physiological situation. In order to characterize the regulatory 
function of murine soluble CD137, two types of experiments will be discussed in this 
section. Firstly, possible correlation of soluble CD137 with certain immune responses 
such as AICD will be examined by comparing the expression of soluble CD137 with 
proliferation and cell death of splenocytes treated with various concentrations of 
activators. Secondly, the effect of soluble CD137 in regulating cytokine secretion will 
be addressed by measuring cytokine concentrations after depletion of soluble CD137 
in vitro. 
 
3.3.1 Correlation of soluble CD137 with AICD 
Levels of soluble CD137 have been shown to be correlated with AICD in man 
(Michel and Schwarz, 2000). It will be interesting to determine whether murine 
soluble CD137 shares the same property. AICD refers to apoptosis induced by 
activation of lymphocytes through their T cell receptor. AICD is hypothesized to play 
essential roles in both central and peripheral deletion events involved in tolerance and 
homeostasis. It eliminates unwanted and potentially dangerous lymphocytes at stages 
of maturation and after activation of mature cells (Zhang et al., 2004). The possible 
70 
 
correlation of soluble CD137 with AICD may indicate that soluble CD137 provides a 
negative control mechanism for immune responses. 
 
Splenoctyes from Balb/C mice were activated for 48 h with Con A titrated from 20 
µg/ml to 0.3 µg/ml. Cell viability was tested by manual cell counting and proliferation 
rates were tested by 3H-thymidine incorporation. Supernatants were harvested for 
testing soluble CD137 by ELISA. In general, levels of soluble CD137 correlated with 
the concentrations of Con A (Figure 21A). Cell viability was low in the conditions 
with 0 and 0.3 µg/ml of Con A. Con A at 0.6 µg/ml rescued many cells from death 
but the death rate increased slightly but continuously with higher Con A 
concentrations (Figure 21B). Proliferation of the cells increased strongly up to 2.5 
µg/ml Con A, but dropped at higher Con A concentrations, likely due to AICD 
(Figure 21C). That would also explain the lower viability at the highest Con A 









Figure 21. Dose dependence of soluble CD137 expression. 3 × 106 splenocytes at a 
concentration of 3 × 106 cells/ml were activated with indicated concentrations of Con 
A. (A) Concentrations of soluble CD137, (B) cell viability and (C) proliferation were 
determined after 48 h. Depicted are means ± SD of triplicate measurements. This 




3.3.2 Soluble CD137 regulates cytokine secretion 
Soluble recombinant CD137-Fc or CD137-AP fusion proteins have been shown to 
antagonize anti-CD3 antibody induced-splenocyte proliferation and IL-2 secretion, 
and mixed lymphocyte reactions (DeBenedette et al., 1995; Hurtado et al., 1995). This 
however could be due to specific characteristics of the recombinant proteins such as 
an Fc domain fused to the CD137 domain thereby enabling the fusion protein to 
induce antibody-dependent cell-mediated cytotoxicity (ADCC) in CD137L-
expressing APC. In order to determine the activity of endogenous soluble CD137, an 
in vitro depletion model was used to measure cytokine release of splenocytes from 
which soluble CD137 has been depleted (Figure 22).  
 
In this model, splenocytes were activated with a suboptimal concentration of Con A 
(2 μg/ml). 24 h and 48 h after activation, the culture medium was removed from cells 
and incubated at 37 ºC for 2 h on plates to which either anti-CD137 antibody or an 
isotype control antibody had been immobilized in order to deplete soluble CD137. 
The cells were cultured in fresh medium during this depletion period and resuspended 
in the soluble CD137 depleted supernatant after the depletion was accomplished. The 
efficiency to deplete soluble CD137 was evaluated by ELISA. In a typical depletion 
experiment, 80 to 90% of soluble CD137 could be depleted from the culture 









Figure 22. Schematic depictation of the model to deplete soluble CD137 from 
splenocytes. 106/ml splenocytes were activated with 2 μg/ml Con A. The culture 
medium was removed from cells after 24 and 48 h and incubated for 2 h on plates to 
which either anti-CD137 antibody or an isotype control had been immobilized before 
it was returned to the cells (A). The efficiency of depletion was verified by measuring 
soluble CD137 in capture well and supernatant (B). The result of a typical depletion 
of soluble CD137 is shown in (C).  
 
 
Before we started the depletion experiment, a pre-test was done to determine the 
density of the splenocytes and concentration of the activator to be used in the actual 
experiments.  0.25 to 2 × 106 /ml splenocytes were activated with 1, 2 or 5 µg/ml of 
Con A. Concentrations of soluble CD137 were determined by ELISA after 48 h 
(Figure 23). Results showed that splenocytes secretes more soluble CD137 when 
cultured at higher densities. The increase of Con A concentrations also brought up 
soluble CD137 levels. For the functional studies of soluble CD137, a suboptimal 
activation status will be favoured because it is likely closer to physiological 
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conditions in vivo. Hence, in the following experiment, 106/ml splenocytes were 
activated with 2 µg/ml of Con A and subjected to soluble CD137 depletion as 
described above.  
 
The experiment was done by depleting soluble CD137 from splenocytes cultures at 24 
and 48 h. After the second depletion, the supernatant was returned to the culture and 
incubated overnight. Soluble CD137-depleted supernatant were then tested for the 
presence of various cytokines, including TNF-α, IL-2, IL-10 and IL-12p70. As shown 
in Figure 24, after the second depletion of soluble CD137 at 48 h only 20% of soluble 
CD137 remained. The reduction in soluble CD137 had no influence on TNF-α and 
IL-2 secretion for the period from 48 to 72 h. However, both IL-12p70 and IL-10 
levels were increased significantly, implying that soluble CD137 inhibits expression 
of these two cytokines (Figure 24). 
 
In this section, the function of endogenous soluble CD137 has been studied for the 
first time by depletion of soluble CD137 from splenocyte cultures. The results show 
an upregulation of IL-10 and IL-12 upon removal of soluble CD137, indicating that 
soluble CD137 inhibits expression of these two cytokines. IL-10 and IL-12 can be 
secreted by various immune cells, which indicate that the effect of soluble CD137 can 
be quite comprehensive. Further studies focusing on each specific type of immune 





Figure 23. Density dependence of soluble CD137 expression. 0.25 - 2 × 106 /ml 
splenocytes were activated with indicated concentrations of Con A. Concentrations of 
soluble CD137 were determined after 48 h. Depicted are means ± SD of triplicate 
measurements. This experiment was performed three times with identical results. 
 
 
Figure 24. Regulation of cytokine secretion by soluble CD137. Soluble CD137 was 
partially depleted from supernatants of splenocyte cultures after 24 and 48 h using 
anti-CD137 antibody (black bars). An isotype control antibody was used as a negative 
control (white bars). After 72 h cytokine levels were measured by ELISA. Means ± 
SD of triplicate measurements are depicted. (* p<0.05; ** p<0.01) 
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3.4 Correlation of soluble CD137 levels with diseases 
Soluble CD137 has been reported to be expressed at elevated levels in sera of patients 
with various diseases. These diseases include autoimmune diseases such as RA 
(Michel et al., 1998; Jung et al., 2004), MS (Sharief, 2002), SLE and BD (Jung et al., 
2004). Recently, increased levels of soluble CD137 were also found in sera of patient 
with various haematological malignancies, especially with CLL (Furtner et al., 2005).  
 
Although soluble CD137 has shown to be correlated with these diseases, none of the 
studies has ever investigated the underlying mechanisms, partially due to the lack of 
appropriate experimental mouse models. Hence, one of the aims of this study was the 
characterization of soluble CD137 with disease activities in mouse models. In this 
section, levels of soluble CD137 will be tested in mouse models to check for potential 
correlations of soluble CD137 with diseases. The result from this part may also help 
to understand the biological relevance of soluble CD137 in vivo.  
 
As soluble CD137 has been found to be expressed in sera of patients with various 
autoimmune diseases, we tested mouse models for autoimmune disease. MRL-Faslpr/J 
(Balb/C lpr), C57/Bl6 MRL-Faslpr/J (C57/Bl6 lpr) and C57/Bl6Smn C3-Faslgld/J 
(C57/Bl6 gld) mice suffer from systemic autoimmunity due to a failure in negative 
selection of developing autoreactive T cells in the thymus. This negative selection is 
mediated by the CD95 receptor/ligand system, and accordingly, mice lacking CD95 
(lpr) or CD95 ligand (gld) are characterized by widespread autoimmunity and 
enhanced immune activity. Concentration of soluble CD137 was tested in sera of 
these autoimmune mice as well as of healthy control mice.  
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Whereas soluble CD137 was not detectable in sera of healthy mice, its levels were 
greatly enhanced in sera of lpr/lpr or gld/gld mice, with mean concentrations around 
10 ng/ml, and peak concentrations above 35 ng/ml (Figure 25). Absence of functional 
CD95 (lpr) or CD95 ligand (gld) had the same effects on soluble CD137 levels. And 
equivalent soluble CD137 levels were measured in lpr sera regardless of whether the 
mutation was on a Balb/C or a C57/Bl6 background (Figure 25). 
 
This result indicates that soluble CD137 is also elevated in sera of mice with 
autoimmune diseases. Hence, the mouse strain MRL-Faslpr/J, C57/Bl6 MRL-Faslpr/J 
and C57/Bl6Smn C3-Faslgld/J can be used in the follow-up studies investigating the 
underlying mechanisms and pathological significance of the presence of soluble 
CD137 in autoimmune diseases. 
 























Figure 25. Levels of soluble CD137 are enhanced in sera of mice with 
autoimmune disease. Soluble CD137 concentrations in sera of 25-week-old female 
healthy mice and mice with autoimmune disease. Each point represents data from one 
mouse. Horizontal bars represent means for each group. (*p<0.05) 
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3.5 Effects of soluble CD137 in tumorigenesis 
CD137 is expressed by certain cancer cells such as Reed Sternberg cells in Hodgkin’s 
lymphoma (unpublished data, H. Schwarz), osteosarcoma (Lisignoli et al., 1998), lung 
cancer (Zhang et al., 2007b), rhabdomyosarcoma and B cell lymphoma (unpublished 
data, B. Z. Quek). In the case of CLL, soluble CD137 was present in 14 out of 14 sera 
from patient samples, but rarely in sera from healthy donors (Furtner et al., 2005). The 
correlation between malignancy and CD137 expression leads to the hypothesis that 
cancer cells may express CD137 as a neoantigen to gain certain survival advantages. 
 
Due to the bidirectional nature of CD137 and CD137L signaling, there are two 
general aspects in which the role of CD137 as a cancer neoantigen can be investigated. 
When CD137 on cancer cells engages CD137L which is expressed on APC, both 
signaling into the APC, as well as signaling via CD137 into the CD137-expressing 
cancer cells may potentially be responsible for conferring a survival advantage upon 
cancer cells. As a result, increased T cell apoptosis, which might be induced by 
CD137-primed monocytes (personal communication, Shaqireen D/O Kwajah), and/or 
enhanced monocyte migration (Drenkard et al., 2007) to the tumor site might be 
observed in the former scenario, while the latter might lead to upregulation of anti-
apoptotic proteins (Lee et al., 2002) in cancer cells. 
 
In this section, CD137-expressing tumor cell lines will be generated by transfection of 
full length CD137 cDNA into tumor cells. The cells that stably express CD137 will be 
selected by their antibiotic resistance provided by the expression vector. The effects 
of CD137 on proliferation, morphology, cytokine secretion and NF-κB activation of 
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these cells will be characterized. The potential protective effect of CD137 on these 
cells will also be examined by both in vitro killing assays and in vivo tumor models. 
 
3.5.1 Screening of tumor cell lines for CD137 expression 
CD137 has been reported to be present in several human tumors, such as Hodgkin’s 
lymphoma (unpublished data, H. Schwarz), osteosarcoma (Lisignoli, et al., 1998), B-
cell lymphoma and rhabdomyosarcoma (unpublished data, B. Z. Quek). However, it 
was not possible to find corresponding mouse models for each individual human 
cancer because many of them are not yet available. Hence, a number of commonly 
used murine tumor cell lines were selected to investigate the potential role of CD137 
in tumor progression. A20 is a mouse B cell lymphoma line isolated from Balb/C 
mice. B16.F0 is a melanoma cell line from C57/Bl6 mice. CT26 is a colon carcinoma 
cell line and 4T1 is a breast cancer cell line, both from Balb/C origin.  
 
These cell lines were first screened for the endogenous expression of CD137 protein. 
The cells were stained with PE-conjugated anti-CD137 antibody 17B5 and analyzed 
by flow cytometry for the expression of membrane-bound CD137. However, none of 
the cells has CD137 expressed on their surface (data not shown).  
 
The expression of CD137 in these cell lines was then analyzed by RT-PCR at mRNA 
levels. Total RNA was extracted from tumor cell line A20, B16.F0, CT26 and 4T1 
and was reverse transcribed to cDNA. PCR was performed using cDNA of these cells 
as template. The primer pair muCD137_F/muCD137_R was designed to amplify the 
full length CD137 cDNA, which was 768 bp. The PCR reaction mix and thermal 
cycling programs for amplifying murine CD137 and the internal control GAPDH are 
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listed in Table 2 and Table 3 in charpter 2. CHO cells stably transfected with murine 
CD137 expression vector Mu_CD137_Neo (CHO-muCD137) or empty vector 
pcDNA 3.1(CHO-pcDNA) were generated previously in our lab and were used as 
positive and negative controls, respectively.  
 
Among the cell lines tested, CD137 was found to be expressed in CT26 and 4T1 cells 
(Figure 26) as shown by the 768 bp band representing full length CD137. For the cell 
lines CT26 and 4T1 there was also a shorter band with a size of 633 bp that was not 
present in the positive control CHO-muCD137 cells. This shorter band could 
represent endogenous soluble CD137 expression in CT26 and 4T1 cells. The absence 
of the soluble CD137 band in the positive control could be explained by the fact that 
only full length but not soluble CD137 cDNA was transfected into CHO-muCD137 
cells.  
 
A20 and B16.F0 cells expressed neither full length nor soluble CD137 at mRNA 
levels (Figure 26). The fact that CT26 and 4T1 cells express CD137 mRNA but not 
protein indicated that there might be inhibitory mechanisms in these cells to prevent 
the transcription of CD137. Hence, A20 and B16.F0 cells were selected to generate 




Figure 26. Screening of CD137 expression of tumor cell lines by RT-PCR. Total 
RNA was extracted from tumor cell lines A20, B16.F0, CT26 and 4T1 and reverse 
transcribed using M-MuLV reverse transcriptase (Fermentas), followed by PCR for 
CD137. The PCR products were separated on 1% agarose gels and visualized by 




3.5.2 Generation of stable, CD137-expressing B16 cell lines 
The reason why stable CD137-expressing cell lines are needed is that expression of 
CD137 by transient transfection can only last for a limited time such as one week. 
Tumor cell lines that stably express CD137 are essential for in vivo experiments 
which usually last for weeks or even months. Also, compared to transiently 
transfected cells, stably transfected cell lines are more consistent in expression and 
function of over-expressed protein because the cDNA of the protein was incorporated 
in the genome of the cells.   
 
B16.F0 is a mouse melanoma cell line that expresses CD137L but not CD137. As 
shown in Figure 27, 36.2% of B16.F0 cells express CD137L while the CD137 
expression was not detectable on the surface of B16.F0 cells. Cells were transfected 
with Mu_CD137_Neo containing the full length murine CD137 cDNA or with the 
empty vector pcDNA3.1(+). These plasmids contain a neomycin resistance gene, and 
stably transfected clones were selected by resistance against the antibiotic Geneticin®. 
 
To determine the dosage required, Geneticin® was titrated and added to untransfected 
B16.F0 cells. 2 × 104 Cells/well were prepared in a 24 well plate and cultured for 24 h. 
Media containing varying concentrations of Geneticin® (0, 0.2, 0.5, 1, 2 and 5 mg/ml) 
were then added to the cultures and the selective media were replenished every 3 to 4 
days. It was found that Geneticin® at a concentration of 1 mg/ml was able to cause 
significant cell death in B16.F0 cells within 5 days, with no cells being alive by day 






Figure 27. Wild type B16.F0 cells express CD137L but not CD137. Cells were 
stained with PE-conjugated anti-CD137 antibody 17B5 (A) or anti-CD137L antibody 
TKS-1 (B), and analyzed by flow cytometry. Numbers denote % of CD137- or 
CD137L- positive cells. Open histograms: isotype control; Filled histograms: anti-




B16.F0 cells were transfected using lipofectamine 2000 according to the 
manufacturer’s protocol. Expression of CD137 by B16/muCD137 variants was 
confirmed by flow cytometry (Figure 28). The variants B16/muCD137-B6 and -C8 
expressed CD137 at higher levels, with 88.9% and 85.1% of cells being CD137-
positive, respectively, while B16/muCD137-B5 cells had a moderate level of CD137 
expression (48.4% CD137-positive cells). Variants transfected with the empty vector 
(i.e. B16/pcDNA-28 and B16/pcDNA-33) expressed no CD137 and were included in 
subsequent experiments as negative controls. Furthermore, there were no observable 








Figure 28. Expression of CD137 on B16 variants. Cells were stained with PE-
conjugated anti-CD137 antibody and analysed by flow cytometry. Numbers denote % 








Proliferation rates of the B16 variants were determined by 3H-thymidine incorporation 
(Figure 29). Untransfected B16.F0 cells had the highest proliferation rate, which was 
141,300 counts per minute (CPM). Proliferation rates of CD137-expressing B16 
variants varied regardless of their expression levels of CD137. B16/muCD137-B6, 
which has the highest levels of CD137 expression, showed similar proliferation rates 
with the moderate CD137-expressing clone B16/muCD137-B5. B16/muCD137-C8, 
which also expressed high levels of CD137, had the lowest proliferation among all the 
variants. The proliferation rates of the two B16/pcDNA clones 28 and 33 also differed 
a lot, with CPM of 96,030 and 126,800, respectively (Figure 29). These data indicate 
that the expression of CD137 does not affect the proliferation of the cells since there 
were no significant differences in proliferation rate among the different B16 variants. 
 
In summary, wild type B16.F0 cells were transfected with a plasmid containing full 
length murine CD137 to generate CD137-expressing B16 variants. Following 
antibiotic selection, three variants with varying levels of CD137 expression (as 
determined by flow cytometry) were established. These variants do not differ 
significantly from those transfected with the empty vector in terms of morphology as 
well as proliferation rate. In the subsequent experiments, the CD137-expressing clone 
B16/muCD137-B6, which has the highest level of CD137 expression, will be studied 







Figure 29. CD137 expression on B16 variants does not affect cell proliferation. 
Cells were plated in a 96 well plate at a density of 104 cells/well. After the cells had 
adhered to the plate, they were serum-starved overnight. The next day, cells were 
once again cultured in the presence of serum, and then pulsed with 3H-thymidine as 
detailed in Section 2.4. Grey bar: untransfected B16.F0 cells; White bar: B16.F0 cells 
stably transfected with pcDNA3.1; Black bar: B16.F0 cells stably transfected with 





3.5.3 Generation of stable, CD137-expressing A20 cell lines 
A20 is a mouse B cell lymphoma that expresses CD137L but not CD137 (Figure 30). 
Unlike B16.F0 cells, A20 cells were resistant to lipid-based transfection methods such 
as lipofectamine 2000. Instead, A20 cells were transfected by nucleofection which is a 
combination of optimized electrical parameters, generated by a special device called 
Nucleofector, with cell-type specific reagents. The cells were transfected with plasmid 
Mu_CD137_Zeo containing the full length murine CD137 cDNA or with the empty 
vector pcDNA3.1/Zeo(+). These plasmids contain a ZeocinTM resistance gene, and 
stably transfected clones were selected by resistance against the antibiotic ZeocinTM. 
 
To determine the dosage required, ZeocinTM was titrated and added to untransfected 
A20 cells at various concentrations (0, 50, 100, 200, 400, 600, 800, and 1000 µg/ml). 
Selective medium was replenished every 3 to 4 days and the percentage of cell death 
of each concentration was determined by trypan blue staining. It was found that 
ZeocinTM at a concentration of 100 µg/ml was able to cause significant cell death in 
A20 cells within 5 days, with no cells being alive by day 14 (data not shown). 
 
Expression of CD137 by A20/muCD137 variants was confirmed by flow cytometry 
(Figure 31). The variants A20/muCD137-D5, -D10 and -G12 expressed CD137 at 
higher levels, with 98%, 95.1% and 95.9% of cells being CD137-positive, 
respectively (Figure 31). A20/muCD137-B9 cells had a moderate level of CD137 
expression (48.4% CD137-positive cells) while A20/muCD137-A5 and -D12 cells 
expressed CD137 at low levels, with 29.7% and 31.3% of CD137-positive cells, 
respectively. Variants transfected with the empty vector (i.e. A20/pcDNA-B3 and 
A20/pcDNA-E5) expressed no CD137 (Figure 31) and were included in subsequent 
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experiments as negative controls. Furthermore, there were no observable differences 
in the morphologies of all the variants which were established (data not shown). 
 
Proliferation rates of the A20/muCD137 variants were determined by 3H-thymidine 
incorporation (Figure 32). No significant difference could be found between 
A20/pcDNA variants and A20/muCD137-D5 and -G12 cells (Figure 32). Interestingly, 
both A20/pcDNA and A20/muCD137 variants showed reduced proliferation rates as 
compared to untransfected A20 cells, indicating the transfection and selection 







Figure 30. Wild type A20 cells express CD137L but not CD137. Cells were stained 
with PE-conjugated anti-CD137 antibody 17B5 (A) or anti-CD137L antibody TKS-1 
(B), and analyzed by flow cytometry. Numbers denote % of CD137- or CD137L- 
positive cells. Open histograms: isotype control; Filled histograms: anti-CD137 





Figure 31. Expression of CD137 on A20 variants. Cells were stained with PE-
conjugated anti-CD137 antibody and analysed by flow cytometry. Numbers denote % 







Figure 32. CD137 expression on A20 variants does not affect cell proliferation. 
Cells were plated in a 96 well plate at a density of 105 cells/well and serum-starved 
overnight. The next day, cells were once again cultured in the presence of serum, and 
then pulsed with 3H-thymidine as detailed in Section 2.4. Grey bar: untransfected A20 
cells; White bars: A20 cells stably transfected with pcDNA3.1; Black bars: A20 cells 




In summary, stable CD137-expressing A20 cells were generated by transfection of 
wild type A20 cells with a plasmid containing full length murine CD137. Following 
antibiotic selection, six A20 variants with different levels of CD137 expression (as 
determined by flow cytometry) were established. Like transfected B16 cells, 
A20/muCD137 variants do not differ significantly from those transfected with the 
empty vector in terms of morphology as well as proliferation rate. In the subsequent 
experiments, the CD137-expressing clone A20/muCD137-D5 and the control clone 




3.5.4 Morphological changes of A20 cells upon agonistic antibody stimulation 
In order to investigate the signaling through CD137 into tumor cells, two agonistic 
anti-CD137 antibody, clones 3H3 and 158321 were used to stimulate the transfected 
cells. A20/muCD137 and A20/pcDNA variants were cultured in the presence of plate-
bound 3H3 or 158321 for 24 h. The morphologic changes of the cells were observed 
and photos were taken directly from the tissue culture plates under an inverted 
microscope (Figure 33). 
 
A20/muCD137 cells were found to spread on tissue culture plate as early as 4 h in 
response to antibody stimulation (data not shown). After 24 hours’ incubation, 
A20/muCD137 cells became attached in the presence of both agonistic antibodies. 
Some of these cells showed a typical spindle shape (Figure 33, black arrows), while 
many other cells displayed long and branched dendritic projections (Figure 33, red 
arrows). These morphological changes were not observed when A20/muCD137 cells 
were treated with rat IgG2a control antibody or when A20/pcDNA cells were cultured 
in the presence of agonistic anti-CD137 antibodies. The results indicate that the 
morphological changes of A20/muCD137 cells were induced specifically by CD137 
signaling. 
 
A similar experiment was done with B16 variants. However, no significant 
morphological changes could be observed upon treatment with agonistic anti-CD137 























































































































































































3.5.5 CD137 signaling into A20 cells activates the NF-κB pathway 
As discussed in 1.1.3, CD137 signaling in T cells involves activation of NF-κB. NF-
κB signaling increases transcription of the anti-apoptotic genes bcl-XL and bfl-1, 
which in turn enhance T cell survival. In order to test whether signal transduction is 
induced by CD137, preliminary studies on the NF-κB pathway were conducted on 
A20/muCD137 cells treated with agonistic anti-CD137 antibodies.   
 
The p65 protein is a subunit of NF-κB family and is involved in the classical pathway 
of NF-κB activation. In an inactivated state, the heterodimer of p65 and p50 proteins 
is located in the cytosol complexed with the inhibitory protein IκBα. A variety of 
extracellular signals can activate the enzyme IκB kinase (IKK) which in turn 
phosphorylates the IκBα protein leading to a dissociation of IκBα and NF-κB. The 
activated NF-κB is then translocated into the nucleus and regulates gene expression. 
Hence, the activation of NF-κB pathway can be measured by quantification of p65 
proteins in the nuclei of the cells (Gilmore, 2006). 
 
The amounts of p65 proteins were measured in the nuclear extracts of A20 variants 
treated with agonistic anti-CD137 antibody 158321 pre-coated on tissue culture plate. 
The results were normalized using the results from A20/pcDNA cells treated with rat 
IgG2a, and the fold changes of p65 in each condition is displayed (Figure 34). When 
treated with rat IgG2a, levels of p65 in A20/muCD137 cells were 40% higher 
compared to those in A20/pcDNA cells. The increase of p65 levels was more 
prominent when CD137 signaling was induced by anti-CD137 antibody. Levels of 
p65 in A20/muCD137 treated with anti-CD137 antibody were 1.7 times higher than 
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those with rat IgG2a treatment, indicating that CD137 signaling in A20/muCD137 
cells activated the NF-κB pathway.  
 
 
Figure 34. NF-κB p65 activation by CD137 signaling in tumor cells. Fold changes 
of p65 protein in nuclear extracts of A20/pcDNA or A20/muCD137 cells treated with 
plate-bound agonistic anti-CD137 (clone 158321) or isotype control antibody (rat 
IgG2a). All readings were normalized on A20/pcDNA cells treated with rat IgG2a 
antibody. Means of two independent experiments ± standard error of mean (SEM) are 
depicted. (* p < 0.05) 
 
 
B16/muCD137 and B16/pcDNA cells were also tested for NF-κB activation. 
However, no significant difference could be found between the two cell types, or in 
B16/muCD137 cells treated with control or agonistic antibodies (data not shown). 
 
The increase of NF-κB activities in A20/muCD137 cells treated with control antibody 
was probably due to the cross-linking of transfected CD137 with CD137L which is 
expressed endogenously by A20 cells. In order to test this possibility the expression of 
CD137L on CD137-expressing A20 variants were determined by flow cytometry. As 
shown in Figure 35, CD137-expressing A20/muCD137-D5 cells did not express 
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CD137L at all, while 95.6% of the control A20/pcDNA-B3 cells expressed CD137L. 
These data indicate that the presence of CD137 leads to a disappearance of CD137L 
on the A20 cells. These data indicate further that CD137L on A20/muCD137 variants 
may be actively engaged by CD137 that is co-expressed by the cells and this 





Figure 35. Expression of CD137L by A20 variants. Cells were stained with PE-
conjugated anti-CD137 or anti-CD137L antibody and analysed by flow cytometry. 
Numbers denote % of positive cells for CD137 and CD137L respectively. Open 




3.5.6 Cytokine secretion of A20 cells upon stimulation of CD137 signaling 
Activation of NF-κB may influence cytokine production which may facilitate tumor 
progression(Siebenlist et al., 1994). In order to find the downstream effects of NF-κB 
activation in A20/muCD137 cells, culture supernatant of anti-CD137 antibody treated 
A20 variants were analyzed for secretion of cytokines. A number of cytokines were 
tested by ELISA, including IL-2, IL-4, IL-6, IL-10, IL-12p70, IL-23, M-CSF, TGF-β 
and TNF-α. All cytokines except IL-10 were below the detection limit of each assay 
kit. The only cytokine that showed a significant difference was IL-10. As shown in 
Figure 36A, A20/pcDNA cells did not secrete detectable levels of IL-10, while IL-10 
expressed by A20/muCD137 cells amounted to 150 pg/ml. Both agonistic antibody, 
clones 158321 and 3H3, increased IL-10 levels by about 80%, resulting in 250 pg/ml 
of IL-10 secretion.  
 
IL-10 is a pleiotropic cytokine that was initially known as cytokine-synthesis-
inhibiting factor. IL-10 is produced by monocytes, macrophages, B cells and activated 
T cells. Several studies have provided evidence for the role of IL-10 in the 
pathogenesis of malignant B cell lymphoproliferation and lymphomas (Finke et al., 
1993; Masood et al., 1995; Blay et al., 1993). Production of IL-10 may confer a 
selective advantage upon B cell malignancies by directly enhancing the survival and 
proliferation of tumor cells and by impairing host immune responses via its 
suppressive effects on macrophages and T cells (Khatri and Caligiuri, 1998). Tumor 
cells secreting IL-10 can activate Stat3 in various immune subsets, such as tumor-
associated macrophages (TAM), immature DC (ImDC), neutrophils and NK cells. 
When Stat3 is activated in these immune cells, their production of immunostimulatory 
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molecules are reduced, and their ability to kill or inhibit tumor cell growth is 
compromised (Kortylewski and Yu, 2008). 
 
Because soluble CD137 can be an antagonist of membrane-bound CD137, levels of 
soluble CD137 were determined in the same culture supernatant by ELISA (Figure 
36B). Enhanced levels of soluble CD137 were released from A20/muCD137 cells in 
response to agonistic antibody treatment. A20/muCD137 cells treated with rat IgG2a 
secreted low level of soluble CD137 (85 pg/ml). However, when the cells were 
stimulated with anti-CD137 antibodies clones 158321 and 3H3, 750 pg/ml and 350 
pg/ml, respectively, of soluble CD137 could be detected. Since A20 cells do not 
express CD137 endogenously and only the full-length CD137 cDNA was transfected 
into the cells when generating stable A20/muCD137 cells, the secreted soluble CD137 
from these cells could be a by-product of membrane-bound CD137 which was 
cleaved from the cell surface by matrix metalloproteinases (MMPs). This shedding 
effect of soluble CD137 is more prominent when the cells were treated with anti-
CD137 antibodies clone 158321 than clone 3H3. Likewise, clone 158321 was also 










Figure 36. Secretion of IL-10 and soluble CD137 by A20/muCD137 cells. 
A20/muCD137 and A20/pcDNA cells were cultured for 24 h in the presence of 
agonistic anti-CD137 antibodies (clones 158321 and 3H3) or isotype control antibody 
(rat IgG2a). Supernatants of the cultures were analyzed by ELISA. Means ± SD of 
triplicate measurements are depicted. The results are representative of three 





The same panel of cytokines (refer to page 96) was also measured in the culture 
supernatant of B16 variants treated with agonistic antibodies. However, none of the 
cytokines showed any difference between treatment with isotype and agonistic anti-
CD137 antibodies (data not shown). Levels of soluble CD137 were also tested. 
B16/muCD137 secreted large amount of soluble CD137 even without adding 
agonistic antibody. The levels of soluble CD137 in rat IgG2a, 158321 and 3H3 treated 
conditions were 1685 pg/ml, 1153 pg/ml and 1428 pg/ml, respectively. There was no 
significant difference between treatment with agonistic antibodies or the control 
antibody, with p-value of 0.819 and 0.918 when compare 158321 and 3H3 to Rat 
IgG2a respectively (Figure 37). These data indicate that the release of soluble CD137 




Figure 37. B16 variants secrete large amounts of soluble CD137. B16/muCD137 
and B16/pcDNA cells were cultured for 24 h in the presence of agonistic anti-CD137 
antibodies (clones 158321 and 3H3) or isotype control antibody (rat IgG2a). 
Supernatants of the cultures were analyzed by ELISA. Means ± SD of triplicate 
measurements are depicted. The results are representative of three independent 




In order to evaluate the levels of membrane-bound and soluble CD137 in 
A20/muCD137 and B16/muCD137 cells, the percentages of CD137 positive cells, the 
mean fluorescence intensities (MFI) of CD137 expression and the concentrations of 
soluble CD137 in culture are summarized in Table 7. Although there was only a 10 % 
difference in the number of CD137 positive cells between A20/muCD137 and 
B16/muCD137 variants the MFI of CD137 expression was 2.6 times higher in 
A20/muCD137 cells, indicating that the expression level of membrane-bound CD137 
is much lower on B16 variants. B16/muCD137 cells have an average secretion of 
1685 pg/ml of soluble CD137, which is 20 times higher than that of A20/muCD137 
cells.  These data indicate that the reason why B16/muCD137 cells did not respond to 
CD137 over-expression and stimulation could be that CD137 expression on the 
surface of B16 cells did not reach the threshold level necessary for eliciting a cellular 
response. Also, the high levels of soluble CD137 in supernatants should be a by-
product of membrane-bound CD137 which may in turn interfere with CD137 function.  
 
 
Table 7. Comparison of membrane-bound CD137 and soluble CD137 between 
CD137-expressing A20 and B16 variants. 
Cells/variants 
Membrane-bound CD137 Soluble CD137 
(pg/ml) Percentage (%) MFI 
A20/muCD137-D5 98.4 ± 0.7 132.6 ± 8.2 85 ± 1 
B16/muCD137-B6 86.1 ± 4.8 50.3 ± 3.4 1685 ± 72 
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3.5.7 CD137 expression and protection against lymphokine activated killer 
(LAK) cells-mediated cytotoxicity 
To determine if CD137 expression protects cancer cells from being eliminated by 
cytolytic immune cells, in vitro cytotoxicity assays were performed using LAK cells 
and A20 variants as effector and target cells, respectively.  
 
LAK cells refer to cytotoxic effectors generated by culturing lymphocytes in the 
presence of IL-2 (Grimm and Wilson, 1985). These cells are heterogeneous in 
phenotype, consisting mainly of NK cells (CD3-CD5-CD56+CD16+), as well as a 
small sub-population of T cells (CD3+CD56+) (Schmidt-Wolf et al., 1997). As LAK 
cells can mediate non-MHC-restricted cytotoxicity against cancer cells, they have 
been widely studied for use in human adoptive immunotherapy.  
 
In the cytotoxicity assay, target cells (i.e. A20 variants) were labeled with Calcein 
AM, a membrane-permeable dye that is converted to the fluorescent membrane-
impermeable calcein by intracellular esterases. Subsequently, they were incubated 
with LAK cells at different effector to target (E:T) ratios. Upon lysis, target cells 
released calcein into the supernatant. Therefore, the fluorescence intensity of the 
supernatant is a measurement of the extent of target cell cytotoxicity. A LAK 
sensitive cell line YAC-1, a mouse lymphoma cell line, was included as a positive 
control for LAK-induced killing of target cells. 
 
At all three ratios of E:T tested, YAC-1 cells were most susceptible to LAK-induced 
cell death. At E:T ratio of  10:1, 30:1 and 100:1 cytotoxicity of YAC-1 cells was 32.2 
± 2.4%, 51.7 ± 4.8% and 76.4 ± 2.4%, respectively (Figure 38). Susceptibility of 
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A20/pcDNA cells was lower than that of YAC-1 cells, with 24.7 ± 4.1%, 31.1 ± 3.3% 
and 55.7 ± 7.7%, respectively, of dead cells (Figure 38). A20/muCD137 cells showed 
the lowest cytotoxicity at all three ratios of E:T, with 2.3 ± 3.1%, 18.7 ± 5.0% and 
33.9 ± 8.8%, respectively, of dead cells (Figure 38). These data indicate that CD137 
expression was effective in protecting A20 cells from LAK cell induced killing. 
However, the results obtained here were from only one pair of A20/muCD137 and 
A20/pcDNA cells, further experiments using additional clones need to be done to 
confirm the effects of CD137 in protecting LAK cells induced killing.  
 
B16 variants were not tested for LAK-induced cytotoxicity because they have been 
reported to be resistant to killing induced by NK cells, which is the major effectors in 



























Figure 38. CD137-expressing A20 cells are less susceptible to LAK cells-induced 
cytotoxicity. 3 × 106 cells/ml splenocytes from Balb/C mice were activated by 1000 
U/ml of IL-2 for 4 days to generate LAK cells. Target cells labeled with Calcein-AM 
(Molecular Probes, Invitrogen, CA) were then cocultured with effector LAK cells for 
4 h. Cytotoxicity was determined by measuring the fluorescence intensity of Calcein-
AM been released into supernatant. YAC-1 is a LAK killing-sensitive cell line that 
served as a positive control. Means ± SD of triplicates are depicted. Statistics was 
calculated between A20/pcDNA and A20/muCD137 groups. Similar results were 




3.5.8 in vivo tumor assays 
In order to evaluate the in vivo anti-tumor effect of CD137, two syngeneic mouse 
models were used for subcutaneous injection of stably transfected A20 cells into 
Balb/C mice, and for B16.F0 cells into C57/Bl6 mice, respectively. The presence of a 
tumor in each mouse was observed every other day, and the sizes of the tumors were 
recorded. Once the tumor of any mouse in the group exceeded 1 cm in diameter, all 
the mice were sacrificed. Blood of the mice was collected via cardiac puncture. 
Tumors and spleens were isolated from mice, measured for weights, then fixed in 
paraformaldehyde and embedded in paraffin for histological analysis.  
 
10 Balb/C mice per group were used to generate tumors from A20 cells. The growth 
rate of A20 cells in vivo was relatively slow. A20 tumors were only observable when 
their size reached 0.5 cm in diameter, which took 18 to 20 days in average. When any 
one of the tumors exceeded 1 cm in diameter, which was normally around day 27, all 
mice were sacrificed for further analysis. In the A20/pcDNA group, all mice 
developed visible tumors at the time of termination, while only 5 out of 10 mice in 
A20/muCD137 group developed tumors. The weights of A20/pcDNA and 
A20/muCD137 tumors were 0.186 ± 0.065 g and 0.063 ± 0.077 g, respectively. If the 
5 mice that did not bear any tumors were included and plotted as tumors with size of 0 
g, A20/pcDNA tumors were significantly heavier than A20/muCD137 tumors (p = 
0.001) (Figure 39A). However, if only tumor-bearing mice were counted, the 
difference is no longer significant (Figure 39B). The reason that these mice failed to 
develop tumor in vivo could be very complex. It seems to be premature to conclude 





































Figure 39. In vivo tumor models of A20 cells. 2 × 105 A20/pcDNA or 
A20/muCD137 cells were inoculated per Balb/C mouse subcutaneously to induce 
syngeneic mouse model. All mice were sacrificed when tumor of any mouse in the 
two groups exceeded 1 cm in diameter. The weights of each tumor isolated from mice 
were measured. Each point represents data from one mouse. Horizontal bars represent 
means for each group. Weights of tumors from all mice (mice without tumor growth 
was ploted as zero) (A) or tumor-bearing mice only (B) were presented. This result is 









The growth rate of B16 cells in vivo was much faster than that of A20 cells. B16 
tumors appeared as early as day 9, and the tumors reach 1 cm in diameter within 2 
weeks. The weights of B16/pcDNA and B16/muCD137 tumors were 0.509 ± 0.352 g 
and 0.309 ± 0.218 g, respectively (Figure 40). There was no significant difference in 
tumor weights between the two groups, with p-value of 0.202. The fast growth of B16 
tumors in vivo might increase the difficulty to observe the possible difference between 



















Figure 40. In vivo tumor models of B16 cells. 2 × 105 B16/pcDNA or 
B16/muCD137 cells were inoculated per C57/Bl6 mouse subcutaneously to induce 
syngeneic mouse model. All mice were sacrificed when tumor of any mouse in the 
two groups exceeded 1 cm in diameter. The weights of each tumor isolated from mice 
were measured. Each point represents data from one mouse. Horizontal bars represent 






Expression of soluble CD137 was also tested in sera of mice with A20 and B16 
tumors. There was no significant difference in serum levels of soluble CD137 
between mice bearing A20/pcDNA and A20/muCD137 tumors. However, both of 
them had elevated levels of soluble CD137, with average concentrations of 1.17 ± 
0.35 ng/ml and 1.24 ± 0.27 ng/ml, respectively (Figure 41A). In contrast, in control 
Balb/C mice, soluble CD137 was never detectable in serum (refer to Figure 25), 
indicating that tumor growth induced sCD137 expression. Soluble CD137 was also 
present in sera of mice with B16 tumors, although at lower levels than in sera of mice 
with A20 tumors. However, a significant increase of soluble CD137 concentration 
was observed in sera of mice with CD137-expressing tumors compared to sera of 
mice with control tumors. Moreover, only 2 out of 7 serum samples tested positive for 
soluble CD137 in mice with the control tumors while 6 out of 8 mice with CD137-
expressing tumors had soluble CD137 (Figure 41B). The differential expression of 
soluble CD137 between B16/pcDNA and B16/muCD137 tumor mice indicates that 
soluble CD137 might be derived from CD137 expression on B16/muCD137 cells. 
Soluble CD137 might be a by-product due to shedding from membrane-bound CD137 
in B16 tumors that entered the circulation from the tumor sites. In contrast, the 
elevated levels of soluble CD137 in both A20/pcDNA and A20/muCD137 tumors 
indicate that the soluble CD137 could be due to a host immune response to this type 
of tumor (B cell lymphoma) induced because in the case of A20 there is not a lot of 
shedding of soluble CD137. Indeed, soluble CD137 has been shown to be present in 









































Figure 41. Expression of soluble CD137 in in vivo tumor models. 2 × 105 tumor 
cells were inoculated per mouse subcutaneously to induce syngeneic mouse model. 
All mice were sacrificed when tumor of any mouse in the two groups exceeded 1 cm 
in diameter. Serum samples were collected from A20 (A) and B16 (B) tumor bearing 
mice. The presence of soluble CD137 in sera from each group was tested by ELISA. 
Each point represents data from one mouse. Horizontal bars represent means for each 







In summary, CD137 did not confer any growth advantage to A20 and B16 cells in the 
in vivo syngeneic tumor models. However, elevated levels of soluble CD137 were 
found in A20 tumors, indicating a correlation of soluble CD137 in B cell lymphoma 
between the murine models and human patients. 
 
3.5.9 Summary 
By transfecting murine CD137 expression vector into tumor cell lines, two stable 
CD137-expressing tumor cell lines were generated, namely A20/muCD137 and 
B16/muCD137 cells. These cells, together with the control cells which were 
transfected with the empty vector, were characterized functionally for differences in 
proliferation, morphology, resistance to in vitro killing and in vivo tumor formation.  
 
CD137 signaling into A20 cells induced morphological changes of the cells, activated 
the NF-κB pathway and led to secretion of IL-10. In contrast, CD137 expression did 
not seem to have such effects on B16 cells. CD137 was able to protect A20 cells 
against LAK-induced killing, A20/muCD137-D5 cells were more resistant to LAK 
cells compared to A20/pcDNA-E5 cells. However, unlike the in vitro killing assays, 
which showed a protective effect of CD137 for tumor cells, results from the in vivo 
tumor assays were not conclusive. There was no significant difference in the growth 
rates of tumors between CD137-expressing and control A20 or B16 cells.  
 
In conclusion, CD137 expression was able to confer survival advantages to A20 cells 
in vitro. However, its effect in vivo needs further characterization.  
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CHAPTER 4 DISCUSSION 
CD137 is a membrane-bound receptor with a well-established role in T cell co-
stimulation (Schwarz et al., 1996). However, its soluble isoforms have been far less 
studied. This project provides for the first time a characterisation of murine soluble 
CD137 as well as some preliminary studies on the role of CD137 in tumorigenesis. 
This chapter begins with a summary of the results obtained in the previous sections. 
These results will be discussed further in several different aspects, focusing on the 
generation, expression, structure and function of soluble CD137. This will be 
followed by a discussion of the potential antagonistic mechanisms of soluble CD137 
and its application. The role of CD137 in tumorigenesis will also be discussed. Lastly, 
this chapter will conclude with suggestions for future directions. 
 
4.1 Summary of results 
The main objective of this study was to identify and characterize a soluble form of 
murine CD137. We have shown that soluble CD137 is secreted from activated 
splenocytes and that its main source is activated T cells. Soluble CD137 is produced 
by both CD4+ and CD8+ T cells; however, its level is slightly higher in CD4+ T cells 
even though expression of membrane-bound CD137 is significantly higher in CD8+ T 
cells. Other immune cells such as Treg and DC can also express soluble CD137. 
Expression levels of soluble CD137 seem to correlate with those of membrane-bound 
CD137 in most cases except for DC. Maturation of DC increases membrane-bound 
but not soluble CD137 expression. The diverse expression profiles of soluble CD137 
in different cell types indicate that soluble CD137 might be involved in multiple 




Members of the TNF and TNF receptor families exist as trimers and depend on 
trimerization for binding and functional activities (Idriss and Naismith, 2000). We 
have found in this study that soluble CD137 exists as a trimer and a higher order 
multimer. This result indicates that soluble CD137 may be able to bind to CD137 
ligand. Indeed, by using a modified ELISA technique, we managed to demonstrate 
that soluble CD137 can bind to both recombinant CD137 ligand protein and CD137 
ligand expressed on a cell surface. These data provide evidence that soluble CD137 
may antagonize membrane-bound CD137 by competitively binding to CD137 ligand. 
 
The function of naturally expressed soluble CD137 has been characterized by 
comparing its expression with the activation status of splenocytes. It was found that 
higher levels of soluble CD137 correlate with cell death rather than with cell 
proliferation. The negative correlation of soluble CD137 with proliferation indicates a 
role of soluble CD137 in AICD. Moreover, by using an in vitro depletion model, we 
have found that by depleting soluble CD137 from splenocytes culture, elevated levels 
of IL-10 and IL-12 can be detected. This result indicates that soluble CD137 has 
inhibitory effect on the secretion of these two cytokines, probably by inhibiting the 
function of membrane-bound CD137. 
 
Another objective of this study was to identify possible roles of CD137 in 
tumorigensis. CD137-expressing tumor cell lines were generated by transfection of a 
vector containing full length CD137 cDNA into tumor cell lines A20 and B16. It was 
found that in response to agonistic anti-CD137 antibodies, CD137-expressing A20 
cells display distinct morphological changes. This is accompanied by activation of the 
NF-κB pathway and the release of IL-10. Compared to A20/pcDNA-E5 cells,  
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A20/muCD137-D5 cells show reduced cell death against LAK-mediated cytotoxicity,  
suggesting a protective effect of CD137 on A20/muCD137-D5 cells in vitro.However, 
such an effect was not observed in vivo, as no significant difference could be found 
between the growth rates of tumors formed by CD137-expressing and control A20 
cells. Unlike A20 cells, CD137-expressing B16 cells seemed not to respond to CD137 
crosslinking, probably due to the shedding of CD137 from cell surface. In addition, a 
lack of evidence that CD137 is involved in the pathogenesis of melanoma might is in 
line with the unresponsiveness of B16 cells.  
 
4.2 Expression and generation of soluble CD137 
Evidence for soluble forms of CD137 was first obtained from murine splenocytes and 
thymocytes through the identification of a differential mRNA splice form that lacks 
the exon encoding the transmembrane domain (Setareh et al., 1995). Murine soluble 
CD137 protein was then found in the supernatants of splenic and bone marrow 
derived DC (Wilcox et al., 2002). We have found in this study that murine soluble 
CD137 can be secreted by various types of immune cells including helper T cells, 
cytotoxic T cells, Treg and DC. Among different cell types, the overwhelming 
majority of soluble CD137 seems to be derived from T cells as levels of soluble 
CD137 from activated T cells (25 ng/ml, Figure 8C) are comparable to that from total 
splenocytes (20 ng/ml, Figure 4) but much higher than that from DC (150 pg/ml, 
Figure 13 and 4 ng/ml, Figure 15). However, this is just an approximate comparison 
as the cell numbers in each condition may vary from each other.  
 
The expression levels of soluble CD137 were compared with membrane-bound 
CD137 in each cell types. Considering the in vitro stability of soluble CD137, it was 
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concluded that levels of soluble CD137 correlate with membrane-bound CD137 in 
activated splenocytes and T cell subsets. However, this is not the case in DC, as 
maturation of DC up-regulate expression of membrane-bound but not soluble CD137. 
The function of soluble CD137 in DC is not known yet. However, the differntial 
expression of membrane-bound and soluble CD137 in DC suggests that soluble 
CD137 is not a mere by-product of membrane-bound CD137, but a differentially 
expressed mediator of CD137-related immune responses.   
 
We and others have shown that soluble CD137 could be generated by gene alternative 
splicing (Setareh et al., 1995). However, one could not exclude the possibility that 
part of soluble CD137 was shedding from cell surface. Indeed, we have found the 
presence of soluble CD137 from B16/muCD137 and A20/muCD137 cells which do 
not express soluble CD137 mRNA. The secreted soluble CD137 from these cells 
could be a by-product of membrane-bound CD137 which was cleaved from the cell 
surface by MMPs. These data indicate the possibility that soluble CD137 could be 
cleaved from the surface of immune cells. Further experiments including MMP 
inhibitors will be needed to prove this possibility. 
 
Elevated levels of soluble CD137 have been detected in sera of autoimmune patients 
including rheumatoid arthritis, systemic sclerosis, multiple sclerosis, systemic lupus 
erythematousus and Behcet’s disease (Sharief, 2002; Michel et al., 1998; Jung et al., 
2004; Hamaguchi et al., 2009). Also certain hematological malignancies, especially 
chronic lymphocytic leukemia are associated with increased levels of soluble CD137 




We have found in this study the correlation of murine soluble CD137 with SLE-prone 
mouse models. Enhanced levels of soluble CD137 were found in sera of mice lacking 
CD95 (lpr) or CD95L (gld) but not in sera of control Balb/C or C57/Bl6 WT mice. In 
addition, our syngeneic mouse model for B cell lymphoma A20 also shows an overall 
increase of soluble CD137 regardless of the expression of CD137 by A20 cells, 
suggesting that soluble CD137 can be released by the host immune system in 
response to tumorigenesis. The screening of murine disease models for expression of 
soluble CD137 added to our knowledge that similar to its human counterpart, murine 
soluble CD137 can also be released in certain diseases. The correlation of soluble 
CD137 with murine disease models may provide powerful tools for future in vivo 
studies of murine soluble CD137. 
 
4.3 Soluble CD137 antagonizes membrane-bound CD137 
Previous studies have shown that recombinant soluble CD137 protein antagonizes the 
activity of membrane-bound CD137 and abolishes CD137-mediated T cell activation 
(DeBenedette et al., 1995; Hurtado et al., 1995). Although results from these studies 
provide evidence for the possible antagonistic role of soluble CD137 on membrane-
bound CD137, there was no direct evidence that naturally occurring soluble CD137 
has the same antagonistic functions. In this study, we have characterized for the first 
time the antagonistic effects of naturally produced soluble CD137. 
 
4.3.1 Mechanisms of action of soluble CD137 
There are two possible mechanisms how soluble CD137 can antagonize the activities 
of membrane-bound CD137. First, it can compete with membrane-bound CD137 for 
binding to CD137L (Figure 3B). Second, it can insert itself into a trimer of 
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membrane-bound CD137 and thereby disrupt the signaling capacity of the trimer 
(Figure 3C). Such a mechanism has been demonstrated for soluble TNF receptors 
(Deng et al, 2005). As members of the TNF and TNF receptor families exist as 
trimers and depend on trimerization for binding and functional activities (Idriss and 
Naismith, 2000), the multimeric status of soluble CD137 could be crucial to its 
function. The existence of soluble CD137 as a trimer would favour a role as a 
competitive inhibitor (first possibility), and a monomeric form of soluble CD137 
would favour a role as a dominant negative inhibitor (second possibility).  
 
Results from Western blot and SEC clearly demonstrate that murine soluble CD137 
exists as a trimer and a high molecular weights form, indicating that soluble CD137 
can bind to CD137L (Figure 16 & 17). Indeed, soluble CD137 can bind to both 
recombinant CD137 ligand protein and CD137 ligand expressed on cell surface 
(Figure 19 & 20). These results indicate that soluble CD137 may be able to 
antagonize membrane-bound CD137 by competitively binding to CD137L. And 
because of the bidirectional signaling induced by the CD137 receptor / ligand 
interaction, soluble CD137 may be able to block the signaling in both directions, 
showing inhibitory effects on both T cells and APC. Indeed, the increase of IL-10 and 
IL-12 secretion in splenocyte cultures after depletion of soluble CD137 demonstrates 
its inhibitory effect.  
 
Monomeric forms of soluble CD137 have not been detected (Figure 17). Therefore, it 
is less likely that soluble CD137 inserts itself into existing membrane-bound CD137 
trimers of other cells (dominant negative inhibitor acting in trans). But soluble CD137 
could still exert inhibitory activities in cis (on the soluble CD137-producing cell itself) 
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by replacing one or two membrane-bound CD137 units in a membrane-bound CD137 
trimer, thereby disrupting the signaling capacity of the membrane-bound CD137 
trimer, and rendering it non-functional. This way soluble CD137-producing T cells 
could regulate their own costimulation through membrane-bound CD137.   
 
4.3.2 Soluble CD137 as a general immunomodulator 
Soluble CD137 interferes with the interaction of CD137 ligand with membrane-bound 
CD137 and inhibits the activities of the CD137 receptor/ligand system. Addition of 
recombinant soluble CD137 protein to murine splenocytes reduced T cell proliferation 
and IL-2 secretion (DeBenedette et al., 1995; Hurtado et al., 1995). As described 
above most immune cells express either CD137 or its ligand. Accordingly, the CD137 
receptor/ligand system is involved in the regulation of activation, proliferation, 
survival and execution of specific functions of most leukocytes (Tamada and Chen, 
2006; Watts, 2005; So et al., 2008; Thum et al., 2009). Therefore, it can be expected 
that soluble CD137 not only inhibits T cell activities but also affects other CD137-
expressing cells such as NK cells and mast cells. At present, no such studies have 
been reported. Due to the bidirectional signaling capacity of the CD137 
receptor/ligand system, CD137 ligand-expressing cells that can receive reverse signals 
through CD137 ligand can also be affected by the inhibitory effects of soluble CD137 
(Figure 2).  
 
Decreasing proliferation caused by increasing concentrations of activators is 
characteristic of activation-induced cell death (AICD). The interaction between 
CD137 and CD137 ligand gives activation signals into both T cells and APC and may 
eventually lead to AICD. We have found in our system that levels of soluble CD137 
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correlate with cell death rather than with cell proliferation. The negative correlation of 
soluble CD137 with proliferation indicates a role of soluble CD137 in AICD. Soluble 
CD137 can interfere with CD137 and CD137L interaction, and in turn inhibit the 
activation of T cells and APC, respectively. In other words, soluble CD137 is not a 
marker for early-phase or low-level lymphocyte activation, but may be a marker for 
cells in or beyond their maximum activation state. 
 
We have found in this study that by depleting soluble CD137 from splenocytes 
culture, elevated levels of IL-10 and IL-12 can be detected. This result indicates that 
soluble CD137 has inhibitory effect on the secretion of these two cytokines, probably 
by inhibiting the function of membrane-bound CD137. It has been reported that 
splenic DC expresses membrane-bound CD137 and that the crosslinking of CD137 on 
DC by CD137 ligand enhances expression of CD80 and CD86, and induces IL-6 and 
IL-12 release (Futagawa et al., 2002; Wilcox et al., 2002). Since IL-10 and IL-12 can 
be secreted by activated DC, it is possible that soluble CD137 blocks the interaction 
between CD137 on DC and CD137 ligand on other splenocytes such as B cells, 
macrophages or DC, thereby reducing IL-10 and IL-12 secretion. 
 
Another explanation of elevated IL-10 upon soluble CD137 depletion may be related 
to CD4+ T cells. Crosslinking of CD137 on activated CD4+ T cells during early stages 
of priming can result in apoptosis which is dependent on IL-10 (Zhang et al., 2007a). 
Since soluble CD137 decreases IL-10, it may be able to enhance survival of 
CD4+ helper T cells, and may therefore not always be inhibitory to immune responses. 
But such diverse activities of soluble CD137 would merely reflect the dichotomy of 
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membrane-bound CD137 activities which can enhance or inhibit immune responses 
depending on the context (Al-Shamkhani, 2004; Myers and Vella, 2005). 
 
We have also found that CD4+ T cells express slightly higher levels of soluble CD137 
but significantly less membrane-bound CD137 compared to CD8+ T cells. Therefore, 
release of soluble CD137 would be expected to inhibit more the activities of CD8+ T 
cells than those of CD4+ T cells. And soluble CD137 may constitute a mechanism 
how CD4+ T cells regulate the activity of CD8+ T cells.  
 
4.4 Applications of soluble CD137 
What distinguishes soluble CD137 from other soluble TNF receptor family members 
is that it is generated by differential splicing rather than proteolytic cleavage, and that 
soluble CD137 expression parallels that of membrane-bound CD137, which is only 
expressed upon activation. Therefore, soluble CD137 serum levels may be a direct 
correlation of membrane-bound CD137. And since soluble CD137 is derived 
predominantly from activated T cells serum soluble CD137 levels reflect the number 
of activated T cells at the time of measurement. In contrast, soluble receptor forms 
that are generated by proteolytic cleavage represent past physiological states. Among 
the other TNF receptor family members soluble CD95 and CD40 are also generated 
by differential splicing. However, there is no evidence that soluble forms of CD95 
and CD40 correlate with their membrane-bound isoforms (Lotz et al., 1996; Eshel et 
al., 2008).  
 
The unique property of serum soluble CD137 to reflect the number of activated T 
cells offers an unique opportunity. It allows the prescreening of patients who are more 
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likely to respond to a CD137 agonist therapy. At least three different clones of 
humanized anti-CD137 antibodies are currently being tested in phase I clinical trials 
(Hong et al., 2000; Son et al., 2004; Sznol et al., 2008). Since antibody therapies are 
expensive such a prescreening would help to preserve healthcare resources, and may 
spare non-responding patients from experiencing side effects without gaining any 
therapeutic benefit.  
 
Also, soluble CD137 and therapeutic CD137 antibodies will neutralize each other. 
Therefore, measurement of soluble CD137 serum levels is necessary in order to 
determine an effective therapeutic antibody dose. Taking into account the dimeric and 
trimeric nature of antibodies and soluble CD137, respectively, then 10 ng/ml of 
soluble CD137 in the serum could neutralize 80 µg of an anti-CD137 antibody in a 70 
kg human patient. In most human patients soluble CD37 levels range from 1 – 10 
ng/ml but peak levels were found at 16 ng/ml (Jung et al., 2004; Michel et al., 1998; 
Sharief, 2002).   
 
The fact that soluble CD137 reflects CD137 expression levels on activated T cells 
makes it an easy marker of measuring the contribution of T cells to an immune or 
autoimmune response. That would be especially useful in scarce tissues, such as 
synovial or cerebrospinal fluid where a direct measurement of the number of T cells 
and their activation status are difficult. Another application could be a high 
throughput screening of serum soluble CD137 levels as a replacement of testing T cell 




Compared to antagonistic antibodies against CD137 and CD137L, soluble CD137 
may be used as a more potent antagonist to down-regulate unwanted immune 
responses. Due to the bidirectional signaling capacity of the CD137 receptor/ligand 
system, CD137L-expressing cells that can receive reverse signals through CD137 
ligand can also be affected by the inhibitory effects of soluble CD137 (Figure 3). By 
competitively binding to CD137L, soluble CD137 could be able to block signaling 
into both CD137-expressing T cells and CD137L-expressing APC, thus achieving a 
more efficient blockage. 
 
4.5 CD137 as a neoantigen 
Membrane-bound CD137 is expressed by certain cancer cells such as Reed Sternberg 
cells in Hodgkin’s lymphoma (unpublished data, H. Schwarz), osteosarcoma 
(Lisignoli et al. 1998), lung cancer (Zhang et al., 2007), rhabdomyosarcoma and B 
cell lymphoma (unpublished data, B. Z. Quek). The fact that CD137 is expressed by 
tumor but not corresponding health tissue suggests that there may be a potential link 
between CD137 expression and cancer progression, and that antagonists of CD137 
(such as soluble CD137) may be effective in anti-cancer treatment.  
 
Due to the bidirectional nature of CD137 receptor/ligand signaling, there are two 
possible mechanisms that CD137 may be ultilized by tumor cells to protect 
themselves. First, tumor cells may be able to receive activation and survival signals 
through CD137. Secondly, CD137 might exert its effects on immune effector cells, 
namely cytotoxic T lymphocytes (CTLs) and NK cells, which are responsible for anti-




4.5.1 Signaling into CD137-expressing tumor cells 
In order to investigate the role of CD137 as a neoantigen, two mouse tumor cell lines 
that stably express murine CD137 were generated. There is no significant difference 
between control and CD137-expressing clones in proliferation and morphology of the 
cells, indicating that by expressing CD137 alone, tumor cells can not gain much 
growth advantage. To test whether CD137 signaling into the tumor cells would affect 
their growth, the cells were treated with agonistic anti-CD137 antibodies. Indeed, 
distinct morphological changes can be observed in A20/muCD137 cells when treated 
with agonistic antibody. These cells became attached to the tissue culture plates, and 
many of them displayed a dendritic cell-like appearance, with long and branched 
dendritic projections. This phenomenon is defined as “B cell spreading”, which 
indicates the activation of malignant B cells (van Kooten et al., 1993). Spreading is a 
common phenomenon in several B cell malignancies, including B-CLL, HCL and 
NHL. Unlike other types of tumor cells, lymphomas are liscensed to move as 
dissemination of lymphomas are mediated by conserved homing programs. This 
unique property gives lymphoma cells an enhanced opportunity for metastasis. 
Furthermore, as a result of their capability to enhance lymphoma dissemination and to 
transduce signals into the cell, promoting cell growth and survival, adhesion receptors 
may contribute to lymphoma aggressiveness (Drillenburg and Pals, 2000). Taken 
together, the morphological changes induced by CD137 signaling may contribute to 
the activation, migration and survival of the cells. 
 
As introduced previously, CD137 signaling can activate NF-κB pathway, which leads 
to the upregulation of several activation and anti-apoptotic genes. To further confirm 
the activation of A20/muCD137 cells, a NF-κB assay was done to verify the 
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downstream signaling of CD137. A20/muCD137 cells have significantly higher levels 
of NF-κB activation as compared to A20/pcDNA cells. The amount of NF-κB in the 
nucleus is further increased when A20/muCD137 cells are treated with agonistic anti-
CD137 antibody. The difference between A20/CD137 and A20/pcDNA cells is 
probably due to the crosslinking of CD137 by CD137L expressed by A20 cells 
endogeously. However, this interaction may not be strong enough to induce 
morphological changes, which are likely to be a downstream event of NF-κB 
activation. 
 
Compared to control A20 cells, CD137-expressing A20 cells secrete significantly 
higher levels of IL-10, which can be enhanced further by addition of agonistic anti-
CD137 antibody. These data indicate that CD137 signaling into B cell lymphoma A20 
stimulate IL-10 production from the cells. Several studies have provided evidence for 
the role of IL-10 in the pathogenesis of malignant B cell lymphoproliferation and 
lymphomas (Blay et al., 1993; Finke et al., 1993; Masood et al., 1995). There are two 
possible mechanisms by which IL-10 may help growth and survival of malignant B 
cells. Firstly, tumor-secreted IL-10 may impair host immune responses by suppressing 
macrophage and T cell functions. IL-10 deactivates or suppresses activated 
macrophage induced cytotoxic activity and inhibits Th1-type immune responses. 
Tumor-derived IL-10 suppresses the necessary cell-mediated responses supported by 
Th1-type cells during cancer. At the same time, IL-10 can directly suppress 
proliferation of alloantigen- or mitogen- stimulated helper T cells. Studies also 
showed that IL-10 preferentially down-regulates Th1-type cell activity by inhibiting 
macrophage and DC costimulatory activities, which are necessary for Th1 type cell 




On the other hand, the effect of IL-10 can be on tumor cells directly. Jurlander et al., 
reported in 1997 the expression of IL-10 receptor on B-CLL cells. They further 
demonstrated that ligand binding and activation of the IL-10 receptor expressed on B-
CLL cells results in the phosphorylation of signal transducer and activator of 
transcription 1 (STAT1) and STAT3 protein. More importantly, although addition of 
IL-10 inhibited B-CLL proliferation, it can enhance B-CLL differentiation and 
significantly reduce the amount of B-CLL cell death caused by hydrocortisone-
induced apoptosis (Jurlander et al., 1997).  
Tumor cells secreting IL-10 can activate Stat3 in various immune subsets, such as 
tumor-associated macrophages (TAM), immature DC (ImDC), neutrophils and NK 
cells. When Stat3 is activated in these immune cells, their production of 
immunostimulatory molecules is reduced, and their ability to kill or inhibit tumor cell 
growth is compromised (Kortylewski & Yu, 2008). 
 
The influence of IL-10 on macrophages and their role in tumor progression is well 
characterized. Instead of just being a simple inhibitor of macrophage activation, IL-10 
can induce a distinct macrophage activation program which allows them to acquire a 
M2 phenotype (Goerdt and Orfanos, 1999). These alternatively activated M2 
macrophages commonly infiltrate tumor masses to support tumor growth and are 
therefore known as TAM. In addition, IL-10 promotes the differentiation of 
monocytes to mature macrophages and blocks their differentiation to DC (Allavena et 
al., 2000). Thus, IL-10 may be an important determinant of the relative proportion of 
TAM versus inflammatory tumor associated DC. Unlike conventional M1 
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macrophages, these M2 phenotypic TAM support tumor growth and do not initiate 
inflammatory reactions.  
 
In summary, signaling through CD137 into A20 cells triggers the activation of 
classical NF-κB pathway, resulting in the activation of A20 cells. Activated A20 cells 
display a spreading morphology, which is a characteristic for B cell activation. The 
activated A20 cells can also secrete IL-10, which may confer growth and survival 
advantages to tumor cells by directly enhancing the survival and proliferation of 
tumor cells and by impairing host immune responses via its suppressive effects on 
macrophages, DC and T cells. 
 
However, the effects of CD137 signaling seen in A20 cells were not observed in 
another cell line used, the melanoma line B16. These could be due to the fact that 
expression of CD137 may not be involved in the progressing of melanoma. Another 
possible reason is that B16 cells may have some regulatory mechanisms that cleave 
transfected CD137 from the cell surface. As shown in Table 7, B16/muCD137 cells 
have a higher ratio of soluble to membrane-bound CD137 as compared to 
A20/muCD137 cells, indicating that many CD137 proteins expressed by B16 cells 
were cleaved from cell surface. This process was probably due to MMPs. An 
inadequate amount of CD137 on the surface of B16 cells failed to induce any 
significant biological difference. 
 
4.5.2 Effects of tumor-expressing CD137 on host immune cells 
One of the hypotheses as to how CD137 might confer survival advantages upon 
cancer cells is by inhibiting the cytotoxic activities of effector immune cells. Hence, 
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the possible protective effect of CD137 was tested by exposing the cells to LAK cell-
mediated cytotoxicity. Results clearly demonstrate reduced susceptibility to LAK 
cells of CD137-expressing A20 cells compared to the control A20 cells (Figure 38). 
These data indicate that CD137 expression may be effective in protecting A20 cells 
from LAK cell induced killing. However, the results obtained were from only one pair 
of A20/muCD137 and A20/pcDNA cells, further experiments using additional clones 
need to be done to confirm the effects of CD137 in protecting LAK cells induced 
killing.  
 
To further confirm the effect of CD137 in protecting tumor cells, in vivo tumor 
models were induced in syngeneic mouse strains. If CD137 helps with the growth and 
survival of tumors, mice inoculated with CD137-expressing tumor cells should 
develop larger tumors compared to mice with control cells when they were sacrificed 
at the same time.  However, the protective effect of CD137 was not seen in the in vivo 
models. All mice in control group developed visible tumors at the time of termination, 
while only 5 out of 10 mice in A20/muCD137 group had tumors. The failure of 
developing tumors in these mice seems to be a ramdomized event. In a pilot 
experiment using 6 mice per group, all mice in A20/muCD137 group developed 
tumors, while only 3 out of 6 mice in control group had tumors. The reason why some 
of the mice failed to develop tumor is not clear, but it seems to be independent of 
CD137 expression. In addition, there is no significant difference in the weights of the 
excised tumors between the two groups (Figure 39B).  Hence, it is premature to 




One problem with the in vivo experiments is that even in the same group, the 
differences between individual mice can be huge. While some of the mice develop 
tumor very fast, others seem to have much slower tumor growth. By the time the 
largest tumor reach the size limit of 1 cm3 in volume, tumors in other mice might still 
remain hardly recognizable. Another common problem for syngeneic mouse tumor 
models is that these tumors normally have a high growth rate and a short volume 
doubling time. These characteristics make these models very different from naturally 
occurring human tumors, which normally take months or even years to form.  
 
To overcome these problems, these experiments can be repeated with larger numbers 
to exclude outliers. Another option is to use a metastasis model instead of 
subcutaneous injection. As our in vitro data show spreading of A20/muCD137 cells in 
response to CD137 signaling, it is quite likely that the cells may have an enhanced 
ability to dissemination or metastasis. By injecting CD137-expressing tumor cells into 
the tail vein, metastasis of the tumor cells can be tested later by examining target 
organs of the mice, such as lung, liver, kidney and spleen.  
 
In summary, our in vitro data clearly demonstrate that CD137 signaling into A20 cells 
induced the activation of the NF-κB pathway. This activation signal then results in 
morphological changes of the cells, probably mediated by conserved homing 
programs that are retained by malignant B cells during their transformation. The cells 
also have increased levels of IL-10, which may help with the survival of the cells. 
Although results from the in vitro LAK assay show a positive role of CD137 in 
protecting tumor cells against LAK-induced killing, the in vivo syngeneic tumor 
models failed to give similar results. There is no significant difference between 
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A20/muCD137 and control groups in tumor weights. Further experiments using more 
targets or different models may be used to elucidate the role of CD137 in in vivo 
environment. 
  
4.6 Future work 
Soluble CD137 has been identified in man and mouse, and has been associated with 
several autoimmune diseases and cancers. However, it still remains a poorly 
characterized molecule, especially in functional terms. In T cells only inhibition of 
proliferation and IL-2 secretion have been demonstrated so far (DeBenedette et al., 
1995; Hurtado et al., 1995). Although we have shown that depletion of soluble from 
splenocytes resulted in an upregulation of IL-10 and IL-12, the function of soluble 
CD137 in each specific cell type such as DC, B cells, mast cells, monocytes and 
granulocytes has not been addressed.  
 
Data from the human and murine system demonstrate that in activated splenocytes 
membrane-bound and soluble CD137 are expressed at comparable levels and kinetics 
(Michel and Schwarz, 2000). The expression of an activator (membrane-bound 
CD137) and its inhibitor (soluble CD137) by the same cell at the same time seems 
counterintuitive. Future studies need to show whether soluble CD137 parallels 
expression of murine CD137 in all situations. Also, the in vivo half life of soluble 
CD137 is not known, and the inhibitory potential of soluble CD137 depends on its 
ability to remain present in the serum and especially in the inflamed tissue.  
The biology of CD137 and its ligand became more complex when it was discovered 
that CD137 agonists not only enhance T cell activity, but under certain situations can 
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also induce apoptosis of CD4+ T cells, and ameliorate autoimmune responses. What 
would be the effect of soluble CD137 in such a situation?  
 
We have obtained preliminary data on the role of CD137 in the tumorigenesis of A20 
cells. The positive effects of membrane-bound CD137 on A20 cells need to be further 
confirmed by including CD137 antagonists such as soluble CD137. Alternatively, 
more CD137-expressing and control A20 variants can be included in the experiments 
described in this study. 
 
The two stable cell lines A20 and B16 used in this study were generated by over-
expressing of CD137. However, as overexpression does not always result in the 
biological levels of protein expression, and the insertion of target gene may 
sometimes delete certain important genes, overexpression is not the ideal method to 
study protein function. Hence, more tumor cell lines should be screened for the 
expression of CD137 and the control cell lines should be generated by gene silencing. 
The effects of CD137 in tumorigenesis can then be verified in these cell lines in both 
in vitro and in vivo models.  
 
4.7 Conclusion 
The expression of membrane-bound CD137 is well studied in man and mouse, and 
soluble forms of human CD137 have been detected in vitro and in patient sera. These 
findings implied also the existence of soluble forms of murine CD137. In this study, 
murine soluble CD137 has been well characterized in its expression, regulation, 




The characterization of murine soluble CD137 adds to our knowledge of the CD137 
receptor/ligand system. Soluble CD137 is not just an inhibitor of T cell activities but 
it also inhibits dendritic cell functions. Based on the widespread expression of CD137 
and its ligand on leukocytes, and the bidirectional signaling of the CD137 
receptor/ligand system it is highly likely that soluble CD137 will be found to exert 
more widespread inhibitions on immune reactions. However, the soluble CD137 
biology remains only superficially characterized at present. 
 
The correlation of soluble CD137 with diseases and the in vitro expression profile of 
soluble CD137 in the murine system indicate that soluble CD137 has the diagnostic 
potential to assess the number and activation levels of activated T cells. Future 
research will need to validate this and to verify it also in the human system. Then 
soluble CD137 could be used to prescreen patients that are likely to respond to a 
CD137 agonist therapy. 
 
The preliminary results obtained in CD137-expressing A20 cells indicate the role of 
CD137 signaling in the activation and survival of A20 cells in vitro. However, it is 
premature to conclude that CD137 protects A20 cells against host immune responses 
because lack of conclusive in vivo data. Further studies are required to elucidate the 
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APPENDIX I MEDIA AND BUFFERS  
RPMI-1640 
To prepare 1 L of medium: 
Item Quantity Source 
RPMI powder 16.35 g Sigma-Aldrich (St Louis, MO) 
L-glutamine (200 mM) 10 ml Gibco, Invitrogen (Carlsbad, CA)
Sodium bicarbonate 2.0 g Sigma-Aldrich (St Louis, MO) 
MilliQ water Top up to 1 L - 






To prepare 1 L of medium: 
Item Quantity Source 
RPMI-1640 medium 900 ml - 
Fetal Bovine Serum (FBS) 100 ml Biowest (Nuaville, France) 
Sodium pyruvate (100 mM) 10 ml Gibco, Invitrogen (Carlsbad, CA)





To prepare 1 L of medium: 
Item Quantity Source 









Dulbecco's Modified Eagle Medium (DMEM) 
To prepare 1 L of medium: 
Item Quantity Source 
DMED powder 17.6 g Sigma-Aldrich (St Louis, MO) 
L-glutamine (200 mM) 10 ml Gibco, Invitrogen (Carlsbad, CA)
Sodium bicarbonate 3.7 g Sigma-Aldrich (St Louis, MO) 
MilliQ water Top up to 1 L - 






To prepare 1 L of medium: 
Item Quantity Source 
DMED 900 ml - 





To prepare 500 ml of medium: 
Item Quantity Source 
Murine GM-CSF (100 
µg/ml) 
200 µl PeproTech Inc. (Rocky Hill, NJ) 
Murine IL-4 (100 µg/ml) 125 µl PeproTech Inc. (Rocky Hill, NJ) 
RPMI-S2-10-P/S Top up to 500 ml - 







Selection Medium for Transfected A20 Cells 
To prepare 100 ml of medium: 
Item Quantity Source 
RPMI-S2-10 100 ml - 




Selection Medium for Transfected B16 Cells 
To prepare 100 ml of medium: 
Item Quantity Source 
DMEM-10 99 ml - 





To prepare 1 L of solution: 
Item Quantity Source 
NaCl 8 g Sigma-Aldrich (St Louis, MO) 
KCl 0.2 g Sigma-Aldrich (St Louis, MO) 
Na2HPO4 1.44 g Sigma-Aldrich (St Louis, MO) 
KH2PO4 0.24 g Sigma-Aldrich (St Louis, MO) 
MilliQ water Top up to 1L - 







To prepare 50 ml of solution: 
Item Quantity Source 
0.5% Trypsin-EDTA (10 ×) 5 ml Gibco, Invitrogen (Carlsbad, CA)
PBS 45 ml - 





10mM EDTA in PBS 
To prepare 50 ml of solution: 
Item Quantity Source 
0.5 M EDTA solution 1 ml NUMI store, NUS 
PBS 49 ml - 





RBC Lysis Buffer 
To prepare 500 ml of solution: 
Item Quantity Source 
NH4Cl 4.145 g Sigma-Aldrich (St Louis, MO) 
NaHCO3 0.42 g Sigma-Aldrich (St Louis, MO) 
0.5 M EDTA solution 11.5 ml NUMI store, NUS 





Digestion buffer for DC 
To prepare 100 ml of solution: 
Item Quantity Source 
Liberase CI 50 mg Roche (Mannheim, Germany) 
FBS 1 ml Biowest (Nuaville, France) 
RPMI-1640 medium Top up to 100 ml - 





To prepare 100 ml of solution: 
Item Quantity Source 
NaCl 0.85 g Sigma-Aldrich (St Louis, MO) 
0.5 M EDTA solution 200 µl NUMI store, NUS 
HEPES 0.48 g Sigma-Aldrich (St Louis, MO) 




10.88% OptiPrep® solution 
To prepare 10 ml of solution: 
Item Quantity Source 
OptiPrep® density gradient 
medium 
1.852 ml Sigma-Aldrich (St Louis, MO) 







To prepare 500 ml of solution: 
Item Quantity Source 
FBS 10 ml Biowest (Nuaville, France) 
0.5 M EDTA 5 ml NUMI store, NUS 
PBS Top up to 500 ml - 






To prepare 500 ml of solution: 
Item Quantity Source 
FBS 2.5 ml Biowest (Nuaville, France) 
NaH3 0.1 g Sigma-Aldrich (St Louis, MO) 





To prepare 500 ml of solution: 
Item Quantity Source 
FBS 25 ml Biowest (Nuaville, France) 
PBS Top up to 500 ml - 







Lysis Buffer for LAK Assay 
To prepare 50 ml of solution: 
Item Quantity Source 
Triton X-100 50 µl Bio-Rad (Hercules, CA) 
MilliQ water Top up to 50 ml - 





0.05 M Phosphate Citrate Buffer (for TMB Substrate) 
To prepare 100 ml of solution: 
Item Quantity Source 
0.2 M Na2HPO4 solution 25.7 ml Sigma-Aldrich (St Louis, MO) 
0.1 M Citric acid  24.3 ml Sigma-Aldrich (St Louis, MO) 
MilliQ water Top up to 100 ml - 




TMB Substrate Solution 
To prepare 10 ml of solution: 
Item Quantity Source 
TMB tablet 1 tablet Sigma-Aldrich (St Louis, MO) 
0.05 M Phosphate citrate 
buffer 
10 ml - 







To prepare 1 L of solution: 
Item Quantity Source 
Tween-20 500 µl Bio-Rad, Hercules, CA 
PBS Top up to 1 L - 
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APPENDIX II MOCOPLASMA TEST 
To prevent Mycoplasma contamination, all cell lines were routinely checked by PCR-
based tests using the MycoSensorTM PCR Assay kit (Stratagene, La Jolla, CA). The 
detailed protocol is listed as following. 
 
1. Sample preperation 
50 µl of supernatant from cell culture was transferred to a microcentrifuge tube and 
boiled at 95 ºC for 5 min. The supernatant was then mixed with 10 µl of StrataClean 
resin, followed by a short centrifugation. The treated supernatant was harvested as 
template of the PCR tests.  
 
2. PCR mixture preperation 
The reaction mixture was prepared by combining the corresponding components in 
order listed in the table below. 
Components  Stock concentration 
Final 
concentration Volume/Reaction 
Sterile water - - 13.75 µl 
MgCl2 20 mM 2 mM 2.5 µl 
Taq buffer 10 × 1 × 2.5 µl 
dNTP/dUTP mix - - 0.5 µl 
Mycoplasma primer mix - - 1 µl 
Internal control template - - 2 µl 
Taq DNA polymerase 5 U/µl 0.05 U/µl 0.25 µl 
Positive control 
template/test sample 
- - 2.5 µl 
Total reaction volumn - - 25 µl 
 
3. PCR thermal cycling program 
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Step Process  Temperature (ºC) Time 
1 Initial melting 94 10 min 
2 Melting  94 30 sec 
3 Primer annealing 55 1 min 
4 Extension  72 1 min 
5 Repeat step 2-4 for 34 cycles - - 
The PCR products were loaded into 2% agarose gel for electrophoresis and the bands 
were visualized with GelRedTM (Biotrium, Hayward, CA). 
 
4. Typical results 
The Mycoplasma primer mix was designed to amplify a 315-bp PCR product from the 
most common species of Mycoplasma. A 500-bp internal control product was also 
included to ensure the reaction was successful. Typical results from the PCR tests 
were summarized in the table below. 
PCR template PCR product(s) Result 
Cell culture extract + 
internal control template 
None Inhibited PCR 
315 bp and 500 bp Mycoplasma infection 
315 bp only 
Heavy Mycoplasma 
infection 
500 by only No Mycoplasma infection 
Positive control template + 
internal control template 
None Failed PCR 
315 bp only Failed PCR 
315 bp and 500 bp Expected control result 
Negative control template + 
internal control template 
None Failed PCR 
500 bp only Expected control result 





5. Treatment of Mycoplasma contamination 
Cell lines tested positive for Mycoplasma contamination were treated with 0.5 µg/ml 
Mycoplasma removal reagent (AbD Serotec, MorphoSys, Germany) for three 
passages and tested again for the clearance of Mycoplasma contamination. 
 
